STOCK TITAN

FitLife Brands Q3 earnings rise 71% to $1.57M

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
10-Q

Rhea-AI Filing Summary

FitLife Brands, Inc. (FTLF) reported third-quarter revenue of $25.620 million, up 9%, and net income of $1.571 million, up 71% year over year. For the nine months ended September 30, 2026, revenue was $77.494 million, up 40%, and net income was $5.241 million, up 12%. Growth primarily reflected the Irwin acquisition, while Legacy FitLife revenue declined 24% for the quarter and 23% for the nine-month period. Nine-month gross margin was 37.4%, compared with 40.5% a year earlier.

Cash provided by operating activities was $4.445 million, compared with $7.195 million a year earlier. As of September 30, 2026, cash was $0.689 million, total debt was $39.198 million, and $5.2 million was available on the credit line. The company reported compliance with its financial covenants after an October 30, 2026 amendment restated covenants for quarters ending September 30, 2026 through September 30, 2027. Third-quarter restructuring expense was $280,000; FitLife expects annual operating expense reductions of approximately $1.2 million, with savings beginning in the fourth quarter of 2026.

2 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 3 points

How the balance works

Positive

  • Moderate pointNine-month revenue rose 40% to $77.494 million.
  • Moderate pointNine-month net income rose 12% to $5.241 million.

Negative

  • Moderate pointOperating cash flow decreased to $4.445 million from $7.195 million.
  • Moderate pointLegacy FitLife nine-month revenue declined 23%.
  • Moderate pointNine-month gross margin was 37.4%, versus 40.5% in 2025.

Filing Explained

FitLife reports options outstanding and performance stock units. Options add shares only if exercised, while each unit converts into one share only if the 30-day volume-weighted average price meets or exceeds $20, so any issuance would increase the share count and reduce existing holders’ ownership percentages.

Third-quarter revenue $25.620 million Three months ended September 30, 2026; $23.485 million in 2025; up 9%.
Third-quarter net income $1.571 million Three months ended September 30, 2026; $0.921 million in 2025; up 71%.
Nine-month revenue $77.494 million Nine months ended September 30, 2026; $55.548 million in 2025; up 40%.
Nine-month net income $5.241 million Nine months ended September 30, 2026; $4.686 million in 2025; up 12%.
Nine-month gross margin 37.4% Nine months ended September 30, 2026; 40.5% in 2025.
Cash provided by operating activities $4.445 million Nine months ended September 30, 2026; $7.195 million in 2025.
Total debt $39.198 million As of September 30, 2026.
Available credit line $5.2 million Available to borrow as of September 30, 2026.
Adjusted EBITDA financial
"Adjusted EBITDA excludes—in addition to interest"
Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.
Contribution financial
"contribution, a non-GAAP financial measure"
Senior Funded Debt to EBITDA ratio financial
"maximum Senior Funded Debt to EBITDA ratio"
Fixed Charge Coverage Ratio financial
"a minimum Fixed Charge Coverage Ratio"
A fixed charge coverage ratio measures how well a company's operating income can cover its fixed, recurring obligations like interest payments and lease costs. Think of it as a safety margin — the higher the number, the more comfortably a business can pay steady bills from its normal earnings, which matters to investors because it signals financial stability, lower default risk, and greater ability to withstand revenue dips.
cash flow hedge financial
"designated the swap as a cash flow hedge"
A cash flow hedge is an accounting label for a contract or arrangement used to offset expected future swings in a company’s cash payments or receipts — for example from variable-rate interest, foreign currency sales, or forecasted purchases. It matters to investors because it aims to smooth future cash and earnings volatility: gains or losses on the hedge are held out of current profit and reported separately until the underlying transaction affects results, much like buying insurance to steady future bills.
inventory step-up financial
"amortization of inventory step-up"
An inventory step-up is an accounting adjustment made when a business acquisition revalues the purchased company's unsold goods from their old book cost to their current market or fair value, raising the recorded value of that inventory on the balance sheet. This matters to investors because the higher starting value changes future reported profit margins and tax timing—like resetting the price tags in a store, it can make near-term profits look lower even though it doesn't change actual cash sales.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were FTLF's third-quarter 2026 revenue and net income?

For the three months ended September 30, 2026, revenue was $25.620 million and net income was $1.571 million, compared with $23.485 million and $0.921 million, respectively, a year earlier.

What were FTLF's nine-month 2026 revenue and net income?

For the nine months ended September 30, 2026, revenue was $77.494 million and net income was $5.241 million, compared with $55.548 million and $4.686 million, respectively, in 2025.

How much of FTLF's restructuring expense had been paid or accrued?

FitLife recorded $280,000 of restructuring expense during the third quarter of 2026, primarily for severance costs. As of September 30, 2026, $62,000 had been paid and $218,000 remained accrued in accrued expenses.

What did FTLF's October 2026 credit amendment change?

On October 30, 2026, FitLife amended its credit agreement, increasing the maximum Senior Funded Debt to EBITDA ratio for the quarter ended September 30, 2026 and revising financial covenants for subsequent periods through September 30, 2027. The company reported covenant compliance as of September 30, 2026 after the amendment.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Q3 2026 --12-31 false 0001374328 false false false false 1 0 0 0 0 0 0 5 0.333 5 5 0 0 0 0 3 5 1 0 0 2 3 2 2 3 2 3 2 1 1 http://fasb.org/us-gaap/2026#SalesChannelDirectlyToConsumerMember 0 0 00013743282026-01-012026-09-30 thunderdome:item 00013743282026-07-012026-09-30 iso4217:USD 0001374328us-gaap:InterestRateSwapMember2025-01-012025-12-31 0001374328us-gaap:InterestRateSwapMember2026-01-012026-09-30 00013743282026-09-30 0001374328us-gaap:InterestRateSwapMember2026-09-30 xbrli:pure 0001374328us-gaap:InterestRateSwapMember2025-09-05 00013743282025-01-012025-09-30 00013743282025-07-012025-09-30 0001374328us-gaap:NonUsMember2025-01-012025-09-30 0001374328us-gaap:NonUsMember2026-01-012026-09-30 0001374328us-gaap:NonUsMember2025-07-012025-09-30 0001374328us-gaap:NonUsMember2026-07-012026-09-30 0001374328country:US2025-01-012025-09-30 0001374328country:US2026-01-012026-09-30 0001374328country:US2025-07-012025-09-30 0001374328country:US2026-07-012026-09-30 0001374328ftlf:CODMSegmentationMember2025-01-012025-09-30 0001374328ftlf:CODMSegmentationMember2026-01-012026-09-30 0001374328ftlf:CODMSegmentationMember2025-07-012025-09-30 0001374328ftlf:CODMSegmentationMember2026-07-012026-09-30 0001374328ftlf:IrwinNaturalsMember2025-08-082025-09-30 0001374328ftlf:IrwinNaturalsMember2026-01-012026-09-30 0001374328ftlf:IrwinNaturalsMember2026-07-012026-09-30 iso4217:USDxbrli:shares 0001374328ftlf:IrwinNaturalsMember2025-01-012025-09-30 0001374328ftlf:IrwinNaturalsMember2025-07-012025-09-30 0001374328ftlf:IrwinNaturalsMember2025-08-08 0001374328us-gaap:RevolvingCreditFacilityMemberftlf:FirstCitizensBankTrustCompanyMember2025-08-08 0001374328ftlf:IrwinNaturalsMemberus-gaap:RevolvingCreditFacilityMemberftlf:FirstCitizensBankTrustCompanyMember2025-08-082025-08-08 0001374328ftlf:IrwinNaturalsMemberftlf:FirstCitizensBankTrustCompanyMemberftlf:TermLoanMember2025-08-082025-08-08 0001374328ftlf:IrwinNaturalsMember2025-08-082025-08-08 xbrli:shares 00013743282025-12-31 0001374328us-gaap:PerformanceSharesMember2026-09-30 0001374328us-gaap:PerformanceSharesMember2026-01-012026-09-30 0001374328us-gaap:PerformanceSharesMember2026-07-012026-09-30 0001374328us-gaap:PerformanceSharesMember2025-05-31 utr:Y 0001374328us-gaap:PerformanceSharesMember2025-05-012025-05-31 00013743282025-04-012025-04-30 00013743282025-03-012025-03-31 00013743282025-03-012025-04-30 0001374328us-gaap:EmployeeStockOptionMember2025-01-012025-09-30 0001374328us-gaap:EmployeeStockOptionMember2026-01-012026-09-30 0001374328us-gaap:EmployeeStockOptionMember2025-07-012025-09-30 0001374328us-gaap:EmployeeStockOptionMember2026-07-012026-09-30 0001374328us-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementEmployeeMember2026-08-012026-08-31 0001374328us-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementEmployeeMember2026-08-31 0001374328us-gaap:ShareBasedPaymentArrangementEmployeeMember2026-08-31 0001374328us-gaap:ShareBasedPaymentArrangementEmployeeMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2026-08-012026-08-31 0001374328us-gaap:ShareBasedPaymentArrangementEmployeeMember2026-08-012026-08-31 0001374328us-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementEmployeeMember2026-02-012026-05-31 0001374328us-gaap:EmployeeStockOptionMemberus-gaap:ShareBasedPaymentArrangementEmployeeMember2026-05-31 0001374328us-gaap:ShareBasedPaymentArrangementEmployeeMember2026-05-31 0001374328us-gaap:ShareBasedPaymentArrangementEmployeeMember2026-02-012026-05-31 0001374328us-gaap:EmployeeStockOptionMember2026-09-30 0001374328ftlf:RangeTwoMember2026-06-30 0001374328ftlf:RangeTwoMember2026-09-30 0001374328ftlf:RangeTwoMember2026-01-012026-09-30 0001374328ftlf:RangeOneMember2026-06-30 0001374328ftlf:RangeOneMember2026-09-30 0001374328ftlf:RangeOneMember2026-01-012026-09-30 00013743282025-01-012025-12-31 00013743282024-01-012024-12-31 00013743282023-12-31 0001374328ftlf:ShareRepurchaseProgramMember2026-09-30 0001374328ftlf:ShareRepurchaseProgramMember2025-07-012025-09-30 0001374328ftlf:ShareRepurchaseProgramMember2026-07-012026-09-30 0001374328ftlf:ShareRepurchaseProgramMember2025-01-012025-09-30 0001374328ftlf:ShareRepurchaseProgramMember2026-01-012026-09-30 utr:M 0001374328ftlf:ShareRepurchaseProgramMember2023-03-172023-03-17 0001374328ftlf:ShareRepurchaseProgramMember2023-03-17 0001374328ftlf:TermLoansMember2026-09-30 0001374328us-gaap:RevolvingCreditFacilityMember2026-09-30 0001374328us-gaap:RevolvingCreditFacilityMember2025-12-31 0001374328ftlf:FirstCitizensBankTrustCompanyMember2025-12-31 0001374328ftlf:FirstCitizensBankTrustCompanyMember2026-09-30 0001374328ftlf:TermLoansMembersrt:ScenarioForecastMember2027-10-01 0001374328ftlf:TermLoansMembersrt:ScenarioForecastMember2027-06-30 0001374328ftlf:TermLoansMembersrt:ScenarioForecastMember2026-12-31 0001374328ftlf:FirstCitizensBankTrustCompanyMembersrt:ScenarioForecastMember2027-07-012027-09-30 0001374328ftlf:FirstCitizensBankTrustCompanyMembersrt:ScenarioForecastMember2027-01-012027-03-31 0001374328ftlf:FirstCitizensBankTrustCompanyMember2026-01-012026-09-30 0001374328ftlf:FirstCitizensBankTrustCompanyMembersrt:ScenarioForecastMember2027-10-012027-10-01 0001374328ftlf:FirstCitizensBankTrustCompanyMember2025-08-082025-08-08 0001374328ftlf:FirstCitizensBankTrustCompanyMembersrt:MaximumMember2025-08-082025-08-08 0001374328ftlf:FirstCitizensBankTrustCompanyMembersrt:MinimumMember2025-08-082025-08-08 0001374328ftlf:TermLoanMember2025-08-082025-08-08 0001374328ftlf:IrwinNaturalsMemberftlf:IrwinTermLoanMemberftlf:FirstCitizensBankTrustCompanyMember2025-08-082025-08-08 0001374328us-gaap:RevolvingCreditFacilityMemberftlf:FirstCitizensBankTrustCompanyMember2025-08-082025-08-08 0001374328ftlf:IrwinTermLoanMemberftlf:FirstCitizensBankTrustCompanyMember2025-08-08 0001374328ftlf:IrwinTermLoanMemberftlf:FirstCitizensBankTrustCompanyMember2025-08-082025-08-08 0001374328us-gaap:RevolvingCreditFacilityMember2024-10-192024-10-19 0001374328us-gaap:RevolvingCreditFacilityMember2024-10-19 0001374328ftlf:TermLoanBMember2024-10-192024-10-19 0001374328ftlf:TermLoanAMember2024-10-192024-10-19 0001374328ftlf:TermLoansMember2024-10-192024-10-19 0001374328ftlf:TermLoansMember2024-10-19 0001374328us-gaap:RevolvingCreditFacilityMember2023-10-10 0001374328ftlf:TermLoanBMember2023-10-10 0001374328us-gaap:RevolvingCreditFacilityMember2023-02-23 0001374328ftlf:TermLoanAMember2023-02-23 0001374328ftlf:TermLoansAndLinesOfCreditMember2025-12-31 0001374328ftlf:TermLoansAndLinesOfCreditMember2026-09-30 0001374328ftlf:TermLoanMember2025-12-31 0001374328ftlf:TermLoanMember2026-09-30 0001374328us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberftlf:CustomerTwoMember2025-01-012025-12-31 0001374328us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberftlf:CustomerOneMember2025-01-012025-12-31 0001374328us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2025-01-012025-12-31 0001374328us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberftlf:CustomerThreeMember2026-01-012026-09-30 0001374328us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberftlf:CustomerTwoMember2026-01-012026-09-30 0001374328us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberftlf:CustomerOneMember2026-01-012026-09-30 0001374328us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2026-01-012026-09-30 0001374328us-gaap:AccountsPayableMemberus-gaap:SupplierConcentrationRiskMemberftlf:VendorTwoMember2025-01-012025-12-31 0001374328us-gaap:AccountsPayableMemberus-gaap:SupplierConcentrationRiskMemberftlf:VendorOneMember2025-01-012025-12-31 0001374328us-gaap:AccountsPayableMemberus-gaap:SupplierConcentrationRiskMember2025-01-012025-12-31 0001374328us-gaap:AccountsPayableMemberus-gaap:SupplierConcentrationRiskMemberftlf:VendorTwoMember2026-01-012026-09-30 0001374328us-gaap:AccountsPayableMemberus-gaap:SupplierConcentrationRiskMemberftlf:VendorOneMember2026-01-012026-09-30 0001374328us-gaap:AccountsPayableMemberus-gaap:SupplierConcentrationRiskMember2026-01-012026-09-30 0001374328us-gaap:AccountsPayableMemberus-gaap:SupplierConcentrationRiskMemberftlf:VendorThreeMember2025-01-012025-09-30 0001374328us-gaap:AccountsPayableMemberus-gaap:SupplierConcentrationRiskMemberftlf:VendorTwoMember2025-01-012025-09-30 0001374328us-gaap:AccountsPayableMemberus-gaap:SupplierConcentrationRiskMemberftlf:VendorOneMember2025-01-012025-09-30 0001374328us-gaap:AccountsPayableMemberus-gaap:SupplierConcentrationRiskMember2025-01-012025-09-30 0001374328ftlf:InventoryrelatedPurchasesMemberus-gaap:SupplierConcentrationRiskMemberftlf:VendorTwoMember2026-01-012026-09-30 0001374328ftlf:InventoryrelatedPurchasesMemberus-gaap:SupplierConcentrationRiskMemberftlf:VendorOneMember2026-01-012026-09-30 0001374328ftlf:InventoryrelatedPurchasesMemberus-gaap:SupplierConcentrationRiskMember2026-01-012026-09-30 0001374328ftlf:InventoryrelatedPurchasesMemberus-gaap:SupplierConcentrationRiskMemberftlf:VendorThreeMember2025-07-012025-09-30 0001374328ftlf:InventoryrelatedPurchasesMemberus-gaap:SupplierConcentrationRiskMemberftlf:VendorTwoMember2025-07-012025-09-30 0001374328ftlf:InventoryrelatedPurchasesMemberus-gaap:SupplierConcentrationRiskMemberftlf:VendorOneMember2025-07-012025-09-30 0001374328ftlf:InventoryrelatedPurchasesMemberus-gaap:SupplierConcentrationRiskMember2025-07-012025-09-30 0001374328ftlf:InventoryrelatedPurchasesMemberus-gaap:SupplierConcentrationRiskMemberftlf:VendorTwoMember2026-07-012026-09-30 0001374328ftlf:InventoryrelatedPurchasesMemberus-gaap:SupplierConcentrationRiskMemberftlf:VendorOneMember2026-07-012026-09-30 0001374328ftlf:InventoryrelatedPurchasesMemberus-gaap:SupplierConcentrationRiskMember2026-07-012026-09-30 0001374328us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberftlf:CustomerOneMember2025-01-012025-09-30 0001374328us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberftlf:CustomerOneMember2025-07-012025-09-30 0001374328us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberftlf:CustomerOneMember2026-01-012026-09-30 0001374328us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberftlf:CustomerOneMember2026-07-012026-09-30 0001374328us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2026-01-012026-09-30 0001374328us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2026-07-012026-09-30 utr:D 0001374328ftlf:IrwinProductsMember2026-01-012026-09-30 0001374328ftlf:ProductsExcludingIrwinProductsMember2026-01-012026-09-30 0001374328ftlf:IrwinMember2025-01-012025-09-30 0001374328ftlf:IrwinMember2026-01-012026-09-30 0001374328ftlf:IrwinMember2025-07-012025-09-30 0001374328ftlf:IrwinMember2026-07-012026-09-30 0001374328ftlf:LegacyFitLifeMember2025-01-012025-09-30 0001374328ftlf:LegacyFitLifeMember2026-01-012026-09-30 0001374328ftlf:LegacyFitLifeMember2025-07-012025-09-30 0001374328ftlf:LegacyFitLifeMember2026-07-012026-09-30 0001374328us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMembercountry:US2025-01-012025-09-30 0001374328us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMembercountry:US2025-07-012025-09-30 0001374328us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMembercountry:US2026-01-012026-09-30 0001374328us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMembercountry:US2026-07-012026-09-30 0001374328us-gaap:SalesRevenueSegmentMemberus-gaap:CustomerConcentrationRiskMemberftlf:WholesaleSalesMember2025-01-012025-09-30 0001374328us-gaap:SalesRevenueSegmentMemberus-gaap:CustomerConcentrationRiskMemberftlf:WholesaleSalesMember2026-01-012026-09-30 0001374328us-gaap:SalesRevenueSegmentMemberus-gaap:CustomerConcentrationRiskMemberftlf:OnlineSalesMember2025-01-012025-09-30 0001374328us-gaap:SalesRevenueSegmentMemberus-gaap:CustomerConcentrationRiskMemberftlf:OnlineSalesMember2026-01-012026-09-30 0001374328us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberftlf:WholesaleSalesMember2025-07-012025-09-30 0001374328us-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMemberftlf:WholesaleSalesMember2026-07-012026-09-30 0001374328us-gaap:SalesRevenueSegmentMemberus-gaap:CustomerConcentrationRiskMemberftlf:OnlineSalesMember2025-07-012025-09-30 0001374328us-gaap:SalesRevenueSegmentMemberus-gaap:CustomerConcentrationRiskMemberftlf:OnlineSalesMember2026-07-012026-09-30 0001374328us-gaap:SeriesAPreferredStockMember2026-09-30 00013743282025-09-30 00013743282024-12-31 0001374328ftlf:TermLoansMember2025-01-012025-09-30 0001374328ftlf:TermLoansMember2026-01-012026-09-30 0001374328ftlf:The2023TermLoanMember2025-01-012025-09-30 0001374328ftlf:The2023TermLoanMember2026-01-012026-09-30 0001374328ftlf:TermLoanMember2025-01-012025-09-30 0001374328ftlf:TermLoanMember2026-01-012026-09-30 0001374328ftlf:IrwinNaturalsMember2025-01-012025-09-30 0001374328ftlf:IrwinNaturalsMember2026-01-012026-09-30 0001374328us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2025-09-30 0001374328us-gaap:AccumulatedTranslationAdjustmentMember2025-09-30 0001374328us-gaap:RetainedEarningsMember2025-09-30 0001374328us-gaap:AdditionalPaidInCapitalMember2025-09-30 0001374328us-gaap:CommonStockMember2025-09-30 0001374328us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2025-01-012025-09-30 0001374328us-gaap:AccumulatedTranslationAdjustmentMember2025-01-012025-09-30 0001374328us-gaap:RetainedEarningsMember2025-01-012025-09-30 0001374328us-gaap:AdditionalPaidInCapitalMember2025-01-012025-09-30 0001374328us-gaap:CommonStockMember2025-01-012025-09-30 0001374328us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-12-31 0001374328us-gaap:AccumulatedTranslationAdjustmentMember2024-12-31 0001374328us-gaap:RetainedEarningsMember2024-12-31 0001374328us-gaap:AdditionalPaidInCapitalMember2024-12-31 0001374328us-gaap:CommonStockMember2024-12-31 0001374328us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2025-07-012025-09-30 0001374328us-gaap:AccumulatedTranslationAdjustmentMember2025-07-012025-09-30 0001374328us-gaap:RetainedEarningsMember2025-07-012025-09-30 0001374328us-gaap:AdditionalPaidInCapitalMember2025-07-012025-09-30 0001374328us-gaap:CommonStockMember2025-07-012025-09-30 00013743282025-06-30 0001374328us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2025-06-30 0001374328us-gaap:AccumulatedTranslationAdjustmentMember2025-06-30 0001374328us-gaap:RetainedEarningsMember2025-06-30 0001374328us-gaap:AdditionalPaidInCapitalMember2025-06-30 0001374328us-gaap:CommonStockMember2025-06-30 0001374328us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2026-09-30 0001374328us-gaap:AccumulatedTranslationAdjustmentMember2026-09-30 0001374328us-gaap:RetainedEarningsMember2026-09-30 0001374328us-gaap:AdditionalPaidInCapitalMember2026-09-30 0001374328us-gaap:CommonStockMember2026-09-30 0001374328us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2026-01-012026-09-30 0001374328us-gaap:AccumulatedTranslationAdjustmentMember2026-01-012026-09-30 0001374328us-gaap:RetainedEarningsMember2026-01-012026-09-30 0001374328us-gaap:AdditionalPaidInCapitalMember2026-01-012026-09-30 0001374328us-gaap:CommonStockMember2026-01-012026-09-30 0001374328us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2025-12-31 0001374328us-gaap:AccumulatedTranslationAdjustmentMember2025-12-31 0001374328us-gaap:RetainedEarningsMember2025-12-31 0001374328us-gaap:AdditionalPaidInCapitalMember2025-12-31 0001374328us-gaap:CommonStockMember2025-12-31 0001374328us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2026-07-012026-09-30 0001374328us-gaap:AccumulatedTranslationAdjustmentMember2026-07-012026-09-30 0001374328us-gaap:RetainedEarningsMember2026-07-012026-09-30 0001374328us-gaap:AdditionalPaidInCapitalMember2026-07-012026-09-30 0001374328us-gaap:CommonStockMember2026-07-012026-09-30 00013743282026-06-30 0001374328us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2026-06-30 0001374328us-gaap:AccumulatedTranslationAdjustmentMember2026-06-30 0001374328us-gaap:RetainedEarningsMember2026-06-30 0001374328us-gaap:AdditionalPaidInCapitalMember2026-06-30 0001374328us-gaap:CommonStockMember2026-06-30 00013743282026-11-16
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q

 

☒

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2026

 

☐

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from N/A to N/A

 

Commission File No. 000-52369

 

FITLIFE BRANDS, INC.

(Exact name of registrant as specified in its charter)

 

Nevada

 

20-3464383

(State or other jurisdiction of incorporation)

 

(IRS Employer Identification No.)

 

5214 S. 136th Street, Omaha, NE 68137

(Address of principal executive offices)

 

(402) 884-1894 

(Issuer’s telephone number)

 

(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol(s)

Name of each exchange on which

registered

Common Stock, par value $0.01 per share

FTLF

The Nasdaq Capital Market

 

Indicate by check mark whether the Registrant (1) has filed all reports required by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days:   Yes ☒    No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).   Yes ☒    No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

 

Large accelerated filer

☐

Accelerated filer

☐

Non-accelerated filer

☒

Smaller reporting company

☒

   

Emerging growth company

☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐    No ☒

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

 

As of November 16, 2026, a total of 9,391,072 shares of the Registrant’s Common Stock, par value $0.01 per share, were issued and outstanding.

 

 

  

 

FITLIFE BRANDS, INC.

INDEX TO FORM 10-Q FILING

FOR THE QUARTER ENDED SEPTEMBER 30, 2026

 

TABLE OF CONTENTS

 

   

PAGE

PART I - FINANCIAL INFORMATION

 
     

Item 1.

Financial Statements

 
 

Condensed Consolidated Balance Sheets (unaudited)

1
 

Condensed Consolidated Statements of Income and Comprehensive Income (unaudited)

2
 

Condensed Consolidated Statements of Stockholders’ Equity (unaudited)

3
 

Condensed Consolidated Statements of Cash Flows (unaudited)

4
 

Notes to Condensed Consolidated Financial Statements (unaudited)

5
     

Item 2.

Management’s Discussion & Analysis of Financial Condition and Results of Operations

17
     

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

25
     

Item 4.

Controls and Procedures

25
   

PART II - OTHER INFORMATION

 
     

Item 1.

Legal Proceedings

27
     

Item 1A.

Risk Factors

27
     

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

27
     

Item 3.

Defaults Upon Senior Securities

27
     

Item 5.

Other Information

27
     

Item 6.

Exhibits

27

 

 

  

 

Special Note Regarding Forward-Looking Statements

 

This Quarterly Report on Form 10-Q (“Quarterly Report”), including “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Item 2 of Part I of this Quarterly Report, includes forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance, or achievements expressed or implied by forward-looking statements.

 

In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expects”, “plans”, “anticipates”, “believes”, “estimates”, “predicts”, “potential”, “proposed”, “intended”, or “continue” or the negative of these terms or other comparable terminology. You should read statements that contain these words carefully, because they discuss our expectations about our future operating results or our future financial condition or state other “forward-looking” information. There may be events in the future that we are not able to accurately predict or control. Before you invest in our securities, you should be aware that the occurrence of any of the events described in this Quarterly Report could substantially harm our business, results of operations and financial condition, and that upon the occurrence of any of these events, the trading price of our securities could decline and you could lose all or part of your investment. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, growth rates, levels of activity, performance or achievements. We are under no duty to update any of the forward-looking statements after the date of this Quarterly Report to conform these statements to actual results.

 

 

 

 

FITLIFE BRANDS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except per share data)

 
   

September 30, 2026

   

December 31, 2025

 
   

(Unaudited)

         

ASSETS:

               

CURRENT ASSETS

               

Cash and cash equivalents

  $ 689     $ 1,646  

Accounts receivable, net

    8,047       8,765  

Inventories, net

    22,740       21,324  

Prepaid expense and other current assets

    2,140       1,334  

Total current assets

    33,616       33,069  
                 

Property and equipment, net

    52       128  

Right of use asset

    379       682  

Intangibles, net

    50,727       51,440  

Goodwill

    19,333       19,393  

Deferred tax asset

    697       1,525  

Derivative asset

    486       -  

Other assets

    88       83  

TOTAL ASSETS

  $ 105,378     $ 106,320  
                 

LIABILITIES AND STOCKHOLDERS' EQUITY:

               

CURRENT LIABILITIES:

               

Accounts payable

  $ 6,908     $ 6,911  

Accrued expense

    4,602       5,429  

Income taxes payable

    1,801       1,704  

Product returns

    989       1,039  

Term loan – current portion

    6,094       6,094  

Lease liability – current portion

    158       433  

Total current liabilities

    20,552       21,610  
                 

Revolving line of credit

    4,800       5,600  

Term loan, net of current portion and unamortized deferred finance costs

    28,304       32,849  

Long-term lease liability, net of current portion

    227       272  

Derivative liability

    -       26  

Deferred tax liability

    2,242       2,324  

TOTAL LIABILITIES

    56,125       62,681  
                 

STOCKHOLDERS’ EQUITY:

               
Preferred stock, $0.01 par value, 10,000 shares authorized, none outstanding as of September 30, 2026 and December 31, 2025     -       -  

Common stock, $0.01 par value, 120,000 shares authorized; 9,391 issued and outstanding as of September 30, 2026 and December 31, 2025

    94       94  

Additional paid-in capital

    32,384       32,213  

Retained earnings

    17,134       11,893  

Accumulated other comprehensive loss

    (359 )     (561 )

TOTAL STOCKHOLDERS' EQUITY

    49,253       43,639  

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY

  $ 105,378     $ 106,320  

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

1

 

 

FITLIFE BRANDS, INC. 

CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2026 AND 2025

(In thousands, except per share data)

(Unaudited)

 

   

Three months ended September 30

   

Nine months ended September 30

 
   

2026

   

2025

   

2026

   

2025

 
                                 

Revenue

  $ 25,620     $ 23,485     $ 77,494     $ 55,548  

Cost of goods sold

    15,953       14,749       48,499       33,034  

Gross profit

    9,667       8,736       28,995       22,514  
                                 

OPERATING EXPENSE:

                               

Advertising and marketing

    1,585       1,357       4,279       3,601  

Selling, general and administrative

    5,177       4,105       14,895       9,102  

Merger and acquisition related

    -       820       -       1,848  

Depreciation and amortization

    250       136       750       169  

Total operating expense

    7,012       6,418       19,924       14,720  
                                 

OPERATING INCOME

    2,655       2,318       9,071       7,794  
                                 

OTHER EXPENSE (INCOME)

                               

Interest expense, net

    654       562       2,068       955  

Other expense

    -       49       -       49  

Foreign exchange gain

    (35 )     (43 )     (64 )     (57 )

Total other expense

    619       568       2,004       947  
                                 

INCOME BEFORE INCOME TAX PROVISION

    2,036       1,750       7,067       6,847  
                                 

PROVISION FOR INCOME TAXES

    465       829       1,826       2,161  
                                 

NET INCOME

  $ 1,571     $ 921     $ 5,241     $ 4,686  
                                 

NET INCOME PER SHARE

                               

Basic

  $ 0.17     $ 0.10     $ 0.56     $ 0.50  

Diluted

  $ 0.16     $ 0.09     $ 0.53     $ 0.47  

Basic weighted average common shares

    9,391       9,391       9,391       9,332  

Diluted weighted average common shares

    9,907       9,997       9,935       9,962  
                                 

COMPREHENSIVE INCOME:

                               

NET INCOME

  $ 1,571     $ 921     $ 5,241     $ 4,686  

Foreign currency translation adjustment

    3       (42 )     (191 )     98  

Gain (loss) on derivatives, net of tax

    209       (32 )     393       (32 )

Comprehensive income

  $ 1,783     $ 847     $ 5,443     $ 4,752  

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

2

 

 

FITLIFE BRANDS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2026 AND 2025

(In thousands)

(Unaudited) 

 

                                   

Accumulated other

comprehensive income

(loss)

         
   

Common Stock

   

Additional
paid-in

   

Retained

   

Foreign
currency
translation

   

Derivatives

(cash flow

         
   

Shares

   

Amount

   

capital

   

earnings

   

adjustment

   

hedges)

   

Total

 
                                                         

THREE MONTHS ENDED SEPTEMBER 30, 2026

                                                       
                                                         

JULY 1, 2026

    9,391     $ 94     $ 32,288     $ 15,563     $ (729 )   $ 158     $ 47,374  

Stock-based compensation

    -       -       96       -       -       -       96  

Comprehensive income

    -       -       -       -       3       286       289  

Tax effect of derivative

    -       -       -       -       -       (77 )     (77 )

Net income

    -       -       -       1,571       -       -       1,571  

SEPTEMBER 30, 2026

    9,391     $ 94     $ 32,384     $ 17,134     $ (726 )   $ 367     $ 49,253  
                                                         
                                                         

NINE MONTHS ENDED SEPTEMBER 30, 2026

                                                       
                                                         

JANUARY 1, 2026

    9,391     $ 94     $ 32,213     $ 11,893     $ (535 )   $ (26 )   $ 43,639  

Stock-based compensation

    -       -       171       -       -       -       171  

Comprehensive income

    -       -       -       -       (191 )     512       321  

Tax effect of derivative

    -       -       -       -       -       (119 )     (119 )

Net income

    -       -       -       5,241       -       -       5,241  

SEPTEMBER 30, 2026

    9,391     $ 94     $ 32,384     $ 17,134     $ (726 )   $ 367     $ 49,253  
                                                         
                                                         

THREE MONTHS ENDED SEPTEMBER 30, 2025

                                                       
                                                         

JULY 1, 2025

    9,391     $ 94     $ 32,015     $ 9,332     $ (522 )   $ -     $ 40,919  

Stock-based compensation

    -       -       126       -       -       -       126  

Comprehensive income

    -       -       -       -       (42 )     (32 )     (74 )

Net income

    -       -       -       921       -       -       921  

SEPTEMBER 30, 2025

    9,391     $ 94     $ 32,141     $ 10,253     $ (564 )   $ (32 )   $ 41,892  
                                                         
                                                         

NINE MONTHS ENDED SEPTEMBER 30, 2025

                                                       
                                                         

JANUARY 1, 2025

    9,210     $ 92     $ 31,129     $ 5,567     $ (662 )   $ -     $ 36,126  

Exercise of stock options

    181       2       680       -       -       -       682  

Stock-based compensation

    -       -       332       -       -       -       332  

Comprehensive income

    -       -       -       -       98       (32 )     66  

Net income

    -       -       -       4,686       -       -       4,686  

SEPTEMBER 30, 2025

    9,391     $ 94     $ 32,141     $ 10,253     $ (564 )   $ (32 )   $ 41,892  

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

3

 

 

FITLIFE BRANDS, INC. 

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2026 AND 2025

(In thousands)

(Unaudited)

 

   

Nine months ended September 30,

 
   

2026

   

2025

 

CASH FLOWS FROM OPERATING ACTIVITIES:

               

Net income

  $ 5,241     $ 4,686  

Adjustments to reconcile net income to net cash provided by operating activities:

               

Depreciation and amortization

    750       169  

Allowance for credit losses

    57       (19 )

Allowance for inventory obsolescence

    (151 )     154  

Stock-based compensation

    171       332  

Amortization of deferred financing costs

    26       31  

Writeoff of deferred financing costs

    -       49  

Amortization of inventory step-up

    -       392  

Changes in operating assets and liabilities:

               

Accounts receivable - trade

    642       (680 )

Inventories

    (1,177 )     (860 )

Deferred tax asset

    828       77  

Prepaid expense and other assets

    (919 )     (811 )

Right of use asset

    303       139  

Accounts payable

    (93 )     2,980  

Income taxes payable

    (161 )     274  

Lease liability

    (319

)

    (114

)

Accrued expense and other current liabilities

    (702 )     605  

Product returns

    (51 )     (209 )

Net cash provided by operating activities

    4,445       7,195  
                 

CASH FLOWS FROM INVESTING ACTIVITIES:

               

Cash paid for Irwin acquisition

    -       (42,500 )

Purchase of property and equipment

    -       (37 )

Net cash used in investing activities

    -       (42,537 )
                 

CASH FLOWS FROM FINANCING ACTIVITIES:

               

Proceeds from exercise of stock options

    -       682  

Payments on 2025 term loan

    (4,571 )     -  

Payoff of 2023 term loan

    -       (10,875 )

Borrowings on term loans

    -       40,452  

Payments on term loans

    -       (2,250 )

Borrowings on line of credit

    11,800       6,000  

Payments on line of credit

    (12,600 )     -  

Net cash provided by (used in) financing activities

    (5,371 )     34,009  
                 

Foreign currency impact on cash

    (31 )     325  
                 
CHANGE IN CASH AND CASH EQUIVALENTS     (957 )     (1,008 )
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD     1,646       4,520  
CASH AND CASH EQUIVALENTS, END OF PERIOD   $ 689     $ 3,512  
                 

Supplemental cash flow disclosure

               

Cash paid for income taxes

  $ 1,777     $ 2,278  

Cash paid for interest, net of amounts capitalized

  $ 2,045     $ 1,087  

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

4

 

FITLIFE BRANDS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2026 AND 2025

(In thousands, except per share data)

(Unaudited)

 

 

 

NOTE 1 - DESCRIPTION OF BUSINESS

 

Summary

 

FitLife Brands, Inc. (the “Company”) is a provider of innovative and proprietary nutritional supplements and wellness products for health-conscious consumers marketed under the following brand names: (i) NDS Nutrition, PMD Sports, SirenLabs, Core Active, Nutrology, and Metis Nutrition (together, the “NDS Products”); (ii) iSatori, BioGenetic Laboratories, and Energize (together, the “iSatori Products”); (iii) Dr. Tobias, All Natural Advice, and Maritime Naturals (together, the “MRC Products”); (iv) MusclePharm; and (v) Irwin Naturals, Applied Nutrition, and Nature’s Secret (together, the “Irwin Products”).

 

The Company distributes the NDS Products principally through franchised General Nutrition Centers, Inc. (“GNC”) stores located both domestically and internationally. The iSatori Products are sold through retail locations, which include specialty and mass market retailers, as well as online directly to the end consumer. The Company distributes the MRC Products primarily online through e-commerce platforms, such as Amazon, directly to the end consumer. MusclePharm’s products are sold to both wholesale customers as well as online through various e-commerce platforms directly to the end consumer. Irwin Products are sold principally through wholesale channels in mass market and health food store segments, but also online directly to the end consumer.

 

FitLife Brands is headquartered in Omaha, Nebraska. For more information on the Company, please go to www.fitlifebrands.com. The Company’s common stock, par value $0.01 per share (“Common Stock”), trades under the symbol “FTLF” on the Nasdaq Capital Market.

 

 

 

NOTE 2 - BASIS OF PRESENTATION

 

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation are included. Operating results for the three and nine months ended September 30, 2026 are not necessarily indicative of the results that may be expected for the year ending December 31, 2026. Although management of the Company believes the disclosures presented herein are adequate and not misleading, these interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the footnotes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission (the “SEC”) on March 31, 2026.

 

 

 

NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

The Company prepares its financial statements in accordance with accounting principles generally accepted in the U.S. (“GAAP”). Significant accounting policies are as follows:

 

Principles of Consolidation

 

The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. Intercompany accounts and transactions have been eliminated in the condensed consolidated financial statements.

 

Foreign Currency

 

The functional currency of the Company is the U.S. dollar (“USD”). The functional currency of the Company’s Canadian subsidiaries is the Canadian dollar (“CAD”). The assets and liabilities of the Company’s foreign subsidiaries are translated into U.S. dollars using end-of-period exchange rates. Changes in reported amounts of assets and liabilities of foreign subsidiaries that occur as a result of changes in exchange rates between foreign subsidiaries’ functional currencies and the U.S. dollar are included in foreign currency translation adjustment. Foreign currency translation adjustment is included as a component of stockholders’ equity in the accompanying condensed consolidated balance sheets. Revenue and expense transactions use an average rate prevailing during the period of the related transaction. Transaction gains and losses that arise from exchange rate fluctuations denominated in a currency other than the functional currency of each subsidiary are included in the results of operations as incurred.

 

5

 

Use of Estimates and Assumptions

 

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect (i) the reported amounts of assets and liabilities, (ii) the disclosure of contingent assets and liabilities known to exist as of the date the financial statements are published, and (iii) the reported amount of net sales and expense recognized during the periods presented.

 

Those estimates and assumptions include estimates for reserves of uncollectible accounts receivable, allowance for inventory obsolescence, product returns, deals and promotions, depreciable lives of property and equipment, allocation of purchase price from business combinations, analysis of impairment of goodwill, realization of deferred tax assets, accruals for potential liabilities and assumptions made in valuing stock instruments issued for services. Management evaluates these estimates and assumptions on a regular basis. Actual results could differ from those estimates.

 

Revenue Recognition

 

The Company’s revenue is comprised of sales of nutritional supplements and wellness products to consumers.

 

The Company accounts for revenue in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic No. 606, Revenue from Contracts with Customers (“ASC 606”). The underlying principle of ASC 606 is to recognize revenue to depict the transfer of goods or services to customers at the amount expected to be collected. ASC 606 creates a five-step model that requires entities to exercise judgment when considering the terms of contract(s), which includes (1) identifying the contract(s) or agreement(s) with a customer, (2) identifying our performance obligations in the contract or agreement, (3) determining the transaction price, (4) allocating the transaction price to the separate performance obligations, and (5) recognizing revenue as each performance obligation is satisfied. Under ASC 606, revenue is recognized when performance obligations under the terms of a contract are satisfied, which occurs for the Company upon shipment or delivery of products to our customers based on written sales terms. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring the products to a customer.

 

All products sold by the Company are distinct individual products and consist of nutritional supplements and wellness products. The products are offered for sale solely as finished goods, and there are no performance obligations required post-shipment for customers to derive the expected value from them.

 

The Company’s products are also sold on e-commerce platforms including Amazon. For these transactions, the Company evaluated principal versus agent considerations to determine appropriateness of recording distribution and platform fees paid to third-party e-commerce companies as an expense or as a reduction of revenue. The Company records distribution and platform fees to cost of goods sold in the condensed consolidated statements of income and comprehensive income. Distribution and platform fees are not recorded as a reduction of revenue because the Company (1) owns the goods before they are transferred to the customer, (2) can direct Amazon, similar to other third-party logistics providers (“Logistic Providers”), to return the Company’s inventory to any location specified by the Company, (3) has the responsibility to make customers whole following any returns made by customers directly to Logistic Providers and the Company retains the back-end inventory risk, (4) is subject to credit risk (i.e., credit card chargebacks), (5) establishes prices of its products, (6) can determine who fulfills the goods to the customer (Amazon or the Company) and (7) can limit quantities or stop selling the goods at any time. Based on these considerations, the Company is the principal in this arrangement. Advertising fees paid to Amazon are recorded in advertising and marketing expense in the condensed consolidated statements of income and comprehensive income. 

 

The Company disaggregates revenue into distribution channels, geographical regions and collections of brands (Legacy FitLife and recently acquired brands). The Company determines that disaggregating revenue into these categories achieves the disclosure objective to depict how the nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factors.

 

Online revenue, which consists of revenue generated from sales on the Company’s own websites as well as third-party e-commerce platforms such as Amazon, was approximately 46% of net revenue for the three months ended September 30, 2026, compared to 44% of net revenue during the same period in the prior year.  Wholesale revenue was approximately 54% of net revenue for the three months ended September 30, 2026 compared to 56% during the same period in the prior year.

 

Online revenue was approximately 45% of net revenue for the nine months ended September 30, 2026, compared to 56% of net revenue for the nine months ended September 30, 2025. Wholesale revenue was approximately 55% of net revenue for the nine months ended September 30, 2026 compared to 44% of net revenue for the nine months ended September 30, 2025.  

 

Sales to customers in the U.S. were approximately 94% and 95%, respectively, during the three and nine months ended September 30, 2026, and approximately 95% and 96%, respectively, during the three and nine months ended September 30, 2025, with the balance of sales for the same respective periods being to customers primarily in Canada.

 

6

 

The Company provides limited financial performance metrics for two collections of brands—Legacy FitLife (thirteen brands, including MRC and MusclePharm), and Irwin (three brands). These collections of brands do not meet the definition of operating segments and are not managed as such. 

 

   

Three months ended

   

Nine months ended

 
   

September

30, 2026

   

September

30, 2025

   

September

30, 2026

   

September

30, 2025

 
   

(Unaudited)

   

(Unaudited)

 

Legacy FitLife

  $ 12,604     $ 16,664     $ 37,494     $ 48,727  

Irwin

    13,016       6,821       40,000       6,821  

Total revenue

  $ 25,620     $ 23,485     $ 77,494     $ 55,548  

 

Control of products we sell transfers to customers upon shipment from our facilities or delivery to our customers, and the Company’s performance obligations are satisfied at that time. Shipping and handling activities are performed before the customer obtains control of the goods and therefore represent a fulfillment activity rather than promised goods to the customer. Payments for sales are generally made by check, credit card, or wire transfer. Historically the Company has not experienced any significant payment delays from customers.

 

For direct-to-consumer sales, with the exception of Irwin Products, the Company allows for returns within 30 days of purchase. Irwin allows for returns within 60 days of purchase for direct-to-consumer sales. Our wholesale customers may return purchased products to the Company under certain circumstances, which include expired or soon-to-be-expired products located in retail stores or distribution centers, and products that are subject to a recall or that contain an ingredient or ingredients that are subject to a recall by the U.S. Food and Drug Administration (“FDA”).

 

A right of return does not represent a separate performance obligation, but because customers are allowed to return products, the consideration to which the Company expects to be entitled is variable. Such elements of variable consideration include, but are not limited to, estimated sales allowances, defective products, product returns and sales incentives, such as markdowns and sales promotions. The Company uses the most likely amount method to quantify the variable consideration. We assess our contracts and the reasonableness of our conclusions on a quarterly basis.

 

Customer and Vendor Concentration

 

Total net sales to one customer represented 10% of total net revenue for the three and nine months ended September 30, 2026. Sales to a different customer represented 13% and 17% of total net revenue for the three and nine months ended September 30, 2025, respectively. 

 

For the three months ended September 30, 2026, there were two vendors who accounted for 44% and 21% of the Company’s consolidated inventory-related purchases, respectively. For the three months ended September 30, 2025, there were three vendors who accounted for 40%, 33%, and 14% of the Company’s consolidated inventory-related purchases, respectively. For the nine months ended September 30, 2026, there were two vendors who accounted for 44% and 15% of the Company’s consolidated inventory-related purchases, respectively. For the nine months ended September 30, 2025, there were three vendors who accounted for 46%, 16% and 13% of the Company’s consolidated inventory-related purchases, respectively.

 

As of September 30, 2026, there were two vendors who accounted for 32% and 21% of the Company’s consolidated accounts payable, respectively. As of December 31, 2025 there were two vendors who accounted for 40% and 35% of the Company’s consolidated accounts payable, respectively.

 

As of September 30, 2026, there were three customers who accounted for 21%, 13% and 10% of the total accounts receivable balance, respectively. As of December 31, 2025, there were two customers who accounted for 25% and 13% of the total accounts receivable balance, respectively. 

 

Cash and Cash Equivalents

 

The Company considers all highly liquid investments with an original maturity from the date of purchase of three months or less to be cash equivalents.

 

Leases

 

We lease certain corporate office space and office equipment under lease agreements with monthly payments over a period of 36 to 84 months. The Company accounts for its leases in accordance with the guidance of ASC 842, Leases. The Company determines whether a contract is, or contains, a lease at inception. Right-of-use assets represent the Company’s right to use an underlying asset during the lease term, and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at lease commencement based upon the estimated present value of unpaid lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at lease commencement in determining the present value of unpaid lease payments.

 

7

 

Goodwill

 

The Company has determined that it has a single reporting unit for purposes of performing its goodwill impairment test. The Company reviews goodwill for impairment on an annual basis or whenever events or changes in circumstances indicate the carrying value may not be recoverable. The Company first assesses qualitative factors to determine whether it is more-likely-than-not that the fair value of the reporting unit is less than the carrying amount as a basis for determining whether it is necessary to perform an impairment test. If the qualitative assessment warrants further analysis, the Company compares the fair value of the reporting unit to its carrying value. The fair value of the reporting unit is determined using the market approach. The Company determines the amount of a potential goodwill impairment by comparing the fair value of the reporting unit with its carrying amount. To the extent the carrying value of a reporting unit exceeds its fair value, a goodwill impairment charge is recognized.

 

As the Company uses the market approach to determine fair value of the reporting unit, the price of its Common Stock is an important component of the fair value calculation. If the Company’s stock price experiences significant price fluctuations, this will impact the fair value of the reporting unit, which can lead to potential impairment in future periods.

 

Management determined there were no indicators of impairment at September 30, 2026 or December 31, 2025. The Company will perform its annual impairment analysis in December 2026.

 

Intangible Assets

 

The Company has certain intangible assets that were recorded at their fair value at the time of acquisition. The finite-lived intangible assets consist of customer relationships, formulations, and websites. Intangible assets with finite useful lives are amortized using the straight-line method over their estimated useful life.  Intangible assets with indefinite lives, which consist of brands and trademarks, are not amortized but are tested for impairment annually or when indicators of impairment exist. Factors that management considers in this assessment include macroeconomic conditions, industry and market considerations, overall financial performance (both current and projected), changes in management and strategy, and changes in the composition and carrying amounts of net assets. If this qualitative assessment indicates that it is more likely than not that the fair value of the indefinite-lived intangible asset is less than its carrying value, a quantitative assessment is then performed. 

 

The Company noted no indicators of impairment for intangible assets as of September 30, 2026, and December 31, 2025. Intangible asset amortization expense is expected to be approximately $900 for each of the next five years (2026 to 2030).   

 

Acquisitions and Business Combinations

 

The Company allocates the fair value of purchase consideration to the tangible assets acquired, liabilities assumed, and separately identified intangible assets acquired based on their estimated fair values. The excess of the fair value of purchase consideration over the fair values of these identifiable assets and liabilities is recorded as goodwill. Such valuations require management to make significant estimates and assumptions, especially with respect to intangible assets. Significant estimates in valuing certain intangible assets include, but are not limited to, future expected cash flows from acquired trademarks and trade names, useful lives, and discount rates. Management’s estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. During the measurement period, which is the period needed to gather all information necessary to make the purchase price allocation, not to exceed one year from the acquisition date, we may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period, any subsequent adjustments are recorded to earnings.

 

Income Taxes

 

Provision for income taxes consists of current and deferred tax expense. Current tax expense is the expected tax payable on the taxable income for the year using tax rates enacted in the countries where the Company and its subsidiaries operate and generate taxable income. The Company accounts for income taxes using the asset and liability method, whereby deferred tax assets are recognized for deductible temporary differences and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets may also result from unused losses and other deductions carried forward. An assessment of the probability that a deferred tax asset will be recovered is made prior to any deferred tax asset being recognized. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized, or that future deductibility is uncertain.

 

8

 

There is potential for volatility of the effective tax rate due to several factors, including changes in the mix of the pre-tax income and the jurisdictions to which it relates. The effective income tax rate was 25.8% and 31.6% for the nine months ended September 30, 2026 and 2025, respectively.

 

Net Income Per Share

 

Basic net income per share is computed by dividing net income by the weighted average number of common shares outstanding for the period. Diluted earnings per share is computed by dividing the net income available to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued using the treasury stock method. Potential common shares are excluded from the computation when their effect is antidilutive. The dilutive effect of potentially dilutive securities is reflected in diluted net income per share if the exercise prices were lower than the average fair market value of common shares during the reporting period.

 

Basic and diluted weighted-average shares outstanding and antidilutive options that were excluded from diluted weighted average shares outstanding are as follows:

 

   

Three months

ended September 30,

   

Nine months

ended September 30,

 
   

2026

   

2025

   

2026

   

2025

 
                                 

Basic weighted average shares outstanding

    9,391       9,391       9,391       9,332  

Dilutive effect of potential common shares

    516       606       544       630  

Diluted weighted average shares outstanding

    9,907       9,997       9,935       9,962  
                                 

Antidilutive options

    139       30       95       25  

 

Fair Value Measurements

 

The Company uses various inputs in determining the fair value of its investments and measures these assets on a recurring basis. Financial assets recorded at fair value in the balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value. FASB ASC Topic 820, Fair Value, establishes a three-level valuation hierarchy for the use of fair value measurements based upon the transparency of inputs to the valuation of an asset or liability as of the measurement date:

 

 

●

Level 1 – Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.

 

 

●

Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.

 

 

●

Level 3 – Inputs that are both significant to the fair value measurement and unobservable. These inputs rely on management’s own assumptions about the assumptions that market participants would use in pricing the asset or liability. The unobservable inputs are developed based on the best information available in the circumstances and may include the Company’s own data.

 

The carrying amounts of financial assets and liabilities, such as cash and cash equivalents, accounts receivable and accounts payable, approximate their fair values because of the short maturity of these instruments. The carrying value of the Company’s debt approximates its fair value based on the market interest rates of these notes.

 

Segment

 

The Company’s Chief Executive Officer is the chief operating decision maker (“CODM”) and evaluates performance and makes operating decisions about allocating resources based on financial data presented on a consolidated basis. Because the CODM evaluates financial performance on a consolidated basis, the Company has determined that it operates as a single reportable segment composed of the financial results of the Company.

 

9

 

Recently Issued Accounting Pronouncements

 

In November 2024, FASB issued ASU 2024-03 Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40) Disaggregation of Income Statement Expenses (“ASU 2024-03”). The guidance in ASU 2024-03 requires public business entities to disclose in the notes to the financial statements, among other things, specific information about certain costs and expenses including purchases of inventory; employee compensation; and depreciation and amortization expense for each caption on the income statement where such expenses are included. The update is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted, and the amendments may be applied prospectively to reporting periods after the effective date or retrospectively to all periods presented in the financial statements. We are currently evaluating the provisions of this guidance and assessing the potential impact on our financial statement disclosures.

 

Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the SEC did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

 

 

 

NOTE 4 – INVENTORIES

 

The Company’s inventory is carried at the lower of cost or net realizable value using the first-in, first-out (“FIFO”) method. The Company evaluates the need to record adjustments for inventory on a regular basis. Company policy is to evaluate all inventories including components and finished goods for all of its product offerings across all of the Company’s operating subsidiaries.

 

The Company recognizes an allowance for obsolescence for expiring, excess, and slow-moving inventory. To calculate the allowance, the Company analyzes sales projections for each stock-keeping unit (“SKU”) relative to the remaining shelf life of the product. The value of any finished goods inventory projected to expire prior to sale is included in the allowance. 

 

The total allowance for expiring, excess and slow-moving inventory items as of September 30, 2026 and December 31, 2025 amounted to $143 and $247, respectively. The Company’s inventories as of September 30, 2026 and December 31, 2025 were as follows:

 

    September 30, 2026    

December 31, 2025

 
   

(Unaudited)

         

Finished goods

  $ 20,058     $ 19,012  

Components

    2,825       2,559  

Allowance for obsolescence

    (143

)

    (247

)

Total

  $ 22,740     $ 21,324  

 

  

 

NOTE 5 - PROPERTY AND EQUIPMENT

 

The Company had property and equipment as of September 30, 2026 and December 31, 2025 as follows:

 

    September 30, 2026    

December 31, 2025

 
   

(Unaudited)

         

Equipment

  $ 868     $ 869  

Accumulated depreciation

    (816

)

    (741

)

Total

  $ 52     $ 128  

 

Depreciation expense for the three months ended September 30, 2026 and 2025 was $25 and $23, respectively. Depreciation expense for the nine months ended September 30, 2026 and 2025 was $75 and $57, respectively.

 

 

 

NOTE 6 – DEBT

 

Company debt consisted of the following as of September 30, 2026 and December 31, 2025:

 

   

September 30, 2026

   

December 31, 2025

 
                 

Term loan – 2025 Credit Agreement

  $ 34,531     $ 39,102  

Unamortized debt issuance costs

    (133 )     (159 )

Revolving line of credit

    4,800       5,600  

Total debt

    39,198       44,543  

Current portion of term loan

    (6,094 )     (6,094 )

Long-term debt

  $ 33,104     $ 38,449  

 

10

 

Credit Agreements – First Citizens Bank

 

On February 23, 2023, the Company entered into an Amended and Restated Credit Agreement (the “2023 Credit Agreement”) with First Citizens Bank (the “Bank”), amending and restating that certain Credit Agreement, dated September 24, 2019, between the Company and the Bank. Pursuant to the 2023 Credit Agreement, the Bank provided the Company with a term loan for the principal amount of $12,500 (“Term Loan A”), and a revolving line of credit of $3,500 (the “Line of Credit”, and collectively with Term Loan A, the “Prior Loan”). The Company used the proceeds from the Prior Loan to fund the acquisition of MRC and for general working capital purposes.

 

Second Amended and Restated Credit Agreement

 

On October 10, 2023, the Company entered into a Second Amended and Restated Credit Agreement (the “Prior Credit Agreement”) with the Bank, amending and restating the 2023 Credit Agreement between the Company and the Bank. Pursuant to the Prior Credit Agreement, the Bank provided the Company with an additional term loan (“Term Loan B”, and together with Term Loan A, the “Term Loans”) for the principal amount of $10,000 and extended the Line of Credit of $3,500 to December 23, 2024. The Company used the proceeds from Term Loan B to fund the acquisition of the MusclePharm assets and for general working capital purposes.

 

First Amendment to Second Amended and Restated Credit Agreement

 

On December 19, 2024, the Company entered into the First Amendment to the Prior Credit Agreement (the “Amended Prior Credit Agreement”) to extend the Line of Credit to April 30, 2026.

 

Term Loans A and B – Pursuant to the Amended Prior Credit Agreement, the Term Loans accrued interest at a per annum rate equal to the greater of 3.50% or 2.75% above the one-month secured overnight financing rate (“SOFR”) published for such day by the Federal Reserve Bank of New York. The Company was required to make quarterly payments of principal plus accrued interest on the Term Loans until the principal balances were fully amortized. Quarterly principal payments for Term Loan A and Term Loan B were $625 and $500, respectively. The Company was permitted to prepay amounts borrowed under the Term Loans, in whole or in part, with accrued interest to the date of such prepayment on the amount prepaid, by written notice to Bank at least one business day prior to the proposed prepayment.

 

Line of Credit – Also pursuant to the Amended Prior Credit Agreement, outstanding advances under the Line of Credit (“Advances”) accrued interest at a per annum rate equal to the greater of 3.50% or 2.75% above the one-month SOFR, and the Company paid the interest on the Advances monthly, with all principal and any accrued interest on outstanding Advances being due and payable in full on the Line of Credit maturity date. The Company was permitted to prepay amounts borrowed under the Line of Credit, in whole or in part with accrued interest to the date of such prepayment on the amount prepaid, by written notice to Bank at least one business day prior to the proposed prepayment. 

 

Credit Agreement and First Amendment to the Credit Agreement

 

On August 8, 2025 (the “Closing Date”), the Company entered into a Loan, Security and Guarantee Agreement (the “Credit Agreement”) with the Bank. Pursuant to the Credit Agreement, the Bank provided the Company with a five-year term loan in the amount of $40,625 (“Irwin Term Loan”) and a three-year revolving line of credit of up to $10,000 (the “Credit Line”, and collectively with the Irwin Term Loan, the “Loan”). The Company used (i) $29,750 from the Irwin Term Loan to complete the purchase of substantially all of the assets of Irwin (see Note 8); and (ii) $10,875 to pay off, retire and replace the outstanding balance of the Term Loans as of the Closing Date.

 

To secure satisfaction of the Obligations, pursuant to the Credit Agreement, (i) NDS Nutrition Products, Inc., iSatori, Inc., MP Acquisition Corp., and IN Acquisition Corp. (collectively, the “Subsidiaries”) guaranteed the satisfaction of the Obligations by the Company in favor of the Bank and (ii) each of the Subsidiaries and the Company granted a security interest in substantially all of their respective assets in favor of the Bank.

 

Pursuant to the Credit Agreement, the Loan accrues interest at a per annum rate equal to 2.5% to 3.0%, based on leverage, above SOFR published by the Federal Reserve Bank of New York for the applicable selected interest period of one, three or six months (SOFR plus the aforementioned margin or the “Applicable Rate”). The Company began making quarterly payments of principal plus accrued interest on the Irwin Term Loan on December 31, 2025. Principal payments of $1,523 will be made for the next four quarterly payment dates through September 30, 2027, and $2,031 for each quarterly payment thereafter, in each case plus accrued interest. All remaining principal and accrued interest on the Irwin Term Loan will be due and payable in full on August 8, 2030.

 

Outstanding advances under the revolving line of credit will accrue interest at the Applicable Rate, and the Company shall make payments of accrued interest on such advances at the end of each interest period and on the repayment of any advance with all remaining principal and accrued interest on the advances being due and payable in full on August 8, 2028.

 

11

 

The Credit Agreement requires the Company (i) to maintain a maximum Senior Funded Debt to EBITDA ratio (as defined in the Credit Agreement), tested quarterly on a trailing twelve-month basis, and (ii) a minimum Fixed Charge Coverage Ratio (as defined in the Credit Agreement). On October 30, 2026, the Company entered into a First Amendment to the Credit Agreement with the Bank (the “Amended Credit Agreement”). The Amended Credit Agreement restates the financial covenants for quarters ending September 30, 2026 through September 30, 2027 as follows:

 

 

●

Maximum Senior Funded Debt to EBITDA ratio: 3.25 to 1.00 for the quarters ending September 30 and December 31, 2026; 2.75 to 1.00 for March 31 and June 30, 2027; and 2.50 to 1.00 thereafter.

 

●

Minimum Fixed Charge Coverage Ratio: 1.00 to 1.00 for the quarters ending December 31, 2026 and March 31, 2027; 1.10 to 1.00 for June 30 and September 30, 2027; and 1.25 to 1.00 thereafter.

 

After giving effect to the Amended Credit Agreement, the Company was in compliance with its financial covenants as of September 30, 2026.

 

The borrowings outstanding on the Irwin Term Loan were $34,531 and $39,102 as of September 30, 2026 and December 31, 2025, respectively.

 

The borrowings outstanding on the Credit Line were $4,800 and $5,600 as of September 30, 2026 and December 31, 2025, respectively.

 

As of September 30, 2026, the amount available to borrow on the Credit Line was $5,200.

 

Maturities of the Company's Irwin Term Loan are as follows:

 

Year ending

       

2026

  $ 1,523  

2027

    6,602  

2028

    8,125  

2029

    8,125  

2030

    10,156  

Total balance outstanding as of September 30, 2026

  $ 34,531  

 

  

 

NOTE 7 - EQUITY

 

The Company is authorized to issue 120,000 shares of Common Stock, $0.01 par value per share, of which 9,391 shares of Common Stock were issued and outstanding as of September 30, 2026 and December 31, 2025.

 

Share Repurchase Program

 

On May 13, 2025, the Board approved the extension of the Company’s previously authorized share repurchase program, initially approved by the Board on August 16, 2019, as amended on September 23, 2019, November 6, 2019, February 1, 2021 and March 17, 2023 (“Share Repurchase Program”). Under the extended and amended Share Repurchase Program, the Board authorized management to repurchase up to $5,000 of the Company's Common Stock over a period of 24 months, at a purchase price equal to the fair market value of the Company's Common Stock on the date of purchase, with the exact date and amount of such purchases to be determined by management (the “2025 Share Repurchase Program”).

 

During the three and nine months ended September 30, 2026 and 2025, the Company did not repurchase any Common Stock under its share repurchase programs. As of September 30, 2026, the Company retained authorization to purchase $5,000 of Common Stock under the 2025 Share Repurchase Program.

 

12

 

Options

 

Information regarding options outstanding as of September 30, 2026 is as follows:

 

   

Number of

   

Weighted

average

   

Weighted

average

remaining life

 
   

options

   

exercise price

   

(years)

 

Outstanding, December 31, 2024

    977     $ 3.74       3.5  

Issued

    8       18.73          

Exercised

    (181 )     3.78          

Forfeited

    -       -          

Outstanding, December 31, 2025

    804     $ 3.88       3.0  

Issued

    109       10.58          

Exercised

    -       -          

Forfeited

    -       -          

Outstanding, September 30, 2026

    913     $ 4.68       2.6  

 

Outstanding

   

Exercisable

 

Exercise

price per

share

   

Total number

of options

   

Weighted

average

remaining life

(years)

   

Weighted

average

exercise price

   

Number of

vested options

   

Weighted

average

exercise price

 
$0.35 - 2.38       542       2.4    

$

0.77       542    

$

0.77  
$5.77 - 18.73       371       2.9    

$

10.40       253    

$

10.05  
            913       2.6    

$

4.68       795    

$

3.72  

 

The closing stock price for the Company’s Common Stock on September 30, 2026 was $9.30, resulting in an intrinsic value of outstanding options of $4,657.

 

In February 2026 and May 2026, the Company granted stock options to purchase 81 shares of Common Stock to employees. The weighted average exercise price of the stock options granted is $10.85 per share. The stock options expire in five years and vest (i) one third on the first anniversary from the date of grant, and (ii) in two equal annual installments thereafter. The total fair value of these options at grant date was approximately $377, which was determined using a Black-Scholes option pricing model with the following assumptions on a weighted average basis: stock price of $10.85 per share, expected term of four years, volatility of 50%, dividend rate of 0%, and risk-free interest rate of 3.9%. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of measurement corresponding with the expected term of the share option award. The expected term represents the weighted-average period of time that share option awards granted are expected to be outstanding giving consideration to vesting schedules and historical participant exercise behavior. The expected volatility is based upon historical volatility of the Company’s Common Stock. The expected dividend yield is based on the fact that the Company has not paid dividends in the past and does not expect to pay dividends in the future. 

 

In August 2026, the Company granted stock options to purchase 28 shares of Common Stock to employees. The weighted average exercise price of the stock options granted is $9.79 per share. The stock options expire in five years and vest (i) one third on the first anniversary from the date of grant, and (ii) in two equal annual installments thereafter. The total fair value of these options at grant date was approximately $126, which was determined using a Black-Scholes option pricing model with the following assumptions on a weighted average basis: stock price of $9.79 per share, expected term of four years, volatility of 54%, dividend rate of 0%, and risk-free interest rate of 4.2%. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of measurement corresponding with the expected term of the share option award. The expected term represents the weighted-average period of time that share option awards granted are expected to be outstanding giving consideration to vesting schedules and historical participant exercise behavior. The expected volatility is based upon historical volatility of the Company’s Common Stock. The expected dividend yield is based on the fact that the Company has not paid dividends in the past and does not expect to pay dividends in the future. 

 

During the three-month periods ended September 30, 2026 and 2025, the Company recognized stock-based compensation of $51 and $126, respectively, related to stock options. During the nine-month periods ended September 30, 2026 and 2025, the Company recognized stock-based compensation of $103 and $332, respectively, related to stock options. As of September 30, 2026 there is $511 of unamortized stock-based compensation related to stock options. 

 

During the nine months ended September 30, 2025, 181 stock options were exercised pursuant to the terms of the option agreements.  As a result, the Company received cash proceeds of $682, of which $259 was received in March 2025 and the remaining $423 was received during April and May of 2025.

 

Performance Stock Units

 

In May 2026, the Company granted Mr. Ryan Hansen, President, 50 performance stock units (“PSUs”). Each PSU converts into one share of the Company’s Common Stock upon vesting. The PSUs will vest at such date that the 30-day volume-weighted average price of Common Stock meets or exceeds $20. The PSUs expire in five years and are subject to forfeiture in the event Mr. Hansen resigns from his position or is terminated by the Company. As the vesting of the PSUs is subject to certain market conditions, pursuant to current accounting guidelines, the Company determined the fair value to be $336, computed using Monte Carlo simulations on a binomial model with the assistance of a valuation specialist. 

 

13

 

The Company recorded $45 and $68 of stock compensation expense related to PSUs during the three and nine months ended September 30, 2026. As of September 30, 2026, there was $268 of unamortized compensation expense associated with the grant of the PSUs.

 

Warrants

 

The Company issued no warrants to purchase shares of Common Stock during the three and nine months ended September 30, 2026 and 2025. There are no outstanding warrants to purchase shares of Common Stock as of September 30, 2026 and December 31, 2025.

 

 

 

NOTE 8 - ACQUISITION OF IRWIN NATURALS

 

On August 8, 2025, the Company acquired substantially all of the assets and assumed certain liabilities of Irwin through an asset purchase transaction under Section 363 of the U.S. Bankruptcy Code. Total consideration for the acquisition was $42,500. Of this amount, $29,750 was funded using proceeds from a new term loan provided by the Bank and $6,000 was funded from a new $10,000 revolving line of credit from the Bank, with the remainder funded from the Company’s available cash balances.

 

During the nine months ended September 30, 2026, the Company did not incur any transaction-related costs for the acquisition of Irwin.

 

The Company accounted for the acquisition as a business combination under Accounting Standards Codification (“ASC”) 805, Business Combinations. The following table summarizes the fair value of the assets acquired and liabilities assumed on the date of acquisition, and is as follows:

 

   

August 8, 2025

 
         

Accounts receivable

  $ 7,306  

Inventories

    10,754  

Prepaid expense and other current assets

    355  

Right of use asset

    487  

Property and equipment

    69  

Intangible assets

    25,500  

Goodwill

    6,288  

Other non-current assets

    83  

Accounts payable

    (2,056 )

Accrued expense and other current liabilities

    (5,240 )

Product returns

    (533 )

Lease liabilities

    (513 )

Net assets acquired

  $ 42,500  

 

The purchase was intended to augment and diversify the Company’s product offerings and lineup.  Key factors that contributed to the recorded intangible assets and goodwill were the opportunity to complement existing operations of the Company and the opportunity to generate future synergies within the nutritional supplement and wellness business. 

 

14

 

Pro Forma Condensed Combined Financial Information (Unaudited) (In thousands)

 

The following presents the Company’s unaudited pro forma financial information for the three and nine months ended September 30, 2025, giving effect to the acquisition of Irwin as if it had occurred at January 1, 2025. Included in the pro forma information is: removal of Irwin revenue and cost of sales from the nine months ended September 30, 2025 for Irwin business no longer in place as of the closing date (Costco US) as well as removal of CBD revenue due to the Company’s decision to exit the CBD business, fair value adjustment to inventory acquired, transaction-related costs related to the acquisition of Irwin moved from the nine months ended September 30, 2025 to 2024, removal of the interest costs from the Company’s debt prior to the closing of the acquisition, and interest on borrowings made by the Company based on the projected balance of the Irwin Term Loan and revolving line of credit for the respective periods in this pro forma presentation.

 

    Three months ended September 30, 2025    

Nine months ended September 30, 2025

 
                 

Revenue

  $ 28,968     $ 92,246  

Net income

  $ 967     $ 5,188  

Diluted net income per share

  $ 0.10     $ 0.52  

 

The pro forma adjustments do not reflect adjustments for anticipated operating efficiencies that the Company expects to achieve as a result of this acquisition. The pro forma financial information is for informational purposes only and does not purport to present what the Company’s results would actually have been had the transaction actually occurred on the dates presented or to project the combined Company’s results of operations or financial position for any future period. 

 

Irwin revenue for the three and nine months ended September 30, 2026 was $13,016 and $40,000, respectively.

 

Irwin revenue from August 8, 2025 through September 30, 2025 was $6,821.

 

 

 

NOTE 9 – COMMITMENTS AND CONTINGENCIES

 

We are currently not involved in any litigation that we believe could have a material adverse effect on our financial condition or results of operations. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of the Company or any of its subsidiaries, threatened against or affecting the Company, our Common Stock, any of our subsidiaries or of the Company’s or our subsidiaries’ officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect.

 

 

 

NOTE 10 – SEGMENT INFORMATION

 

The Company operates and manages its business as one reportable operating segment dedicated to providing innovative and proprietary nutritional supplements and wellness products for health-conscious consumers.  The measure of segment assets is reported on the condensed consolidated balance sheet as total assets. In addition, the Company manages its business activities on a consolidated basis.

 

The Company’s CODM allocates resources and assesses financial performance based upon financial data presented at the consolidated level.  The CODM uses net income as the sole measure of segment profit. 

 

Significant segment expense categories include cost of goods sold, advertising and marketing, merger and acquisition related and other expense, which are all presented on the condensed consolidated statements of income and comprehensive income.  Employee compensation and benefits is also a significant segment expense.  Operating expense includes all remaining costs necessary to operate our business, including external professional services, insurance and other administrative expenses.  The following table presents the significant segment expenses and other segment items regularly reviewed by our CODM:

 

   

Three months

ended September 30,

   

Nine months

ended September 30,

 
   

2026

   

2025

   

2026

   

2025

 
                                 

Cost of goods sold

  $ 15,953     $ 14,749     $ 48,499     $ 33,034  
                                 

Employee compensation and benefits

    2,871       2,602       9,081       5,633  

Advertising and marketing

    1,585       1,357       4,279       3,601  

Operating expense

    2,556       1,639       6,564       3,638  

Merger and acquisition related

    -       820       -       1,848  

Total operating expense

  $ 7,012     $ 6,418     $ 19,924     $ 14,720  
                                 

Interest and other expense

  $ 619     $ 568     $ 2,004     $ 947  

 

15

 

The following table summarizes sales to customers by geographic regions:

 

   

Three months ended

September 30,

   

Nine months ended

September 30,

 
   

2026

   

2025

   

2026

   

2025

 

United States

  $ 24,013     $ 22,356     $ 73,241     $ 53,172  

Rest of world

    1,607       1,129       4,253       2,376  

Total revenue

  $ 25,620     $ 23,485     $ 77,494     $ 55,548  

 

  

 

NOTE 11 – DERIVATIVE ASSET (INTEREST RATE SWAP)

 

On September 5, 2025, the Company entered into an interest rate swap agreement to hedge exposure to variability in cash flows associated with its variable-rate term loan (see Note 6). The swap effectively converts approximately 50% of the Company’s term loan from variable to fixed.

 

The agreement had a notional amount of $20,000 at inception, amortizes in accordance with the underlying debt, and requires the Company to pay a fixed rate of 3.39% while receiving a variable rate based on SOFR. The agreement expires on August 8, 2030.

 

The Company designated the swap as a cash flow hedge under ASC 815, Derivatives and Hedging. The effective portion of changes in the fair value of the derivative is recorded in Other Comprehensive Income and reclassified into interest expense as payments occur under the hedged debt.

 

The fair value of the swap was an asset of $486 at September 30, 2026 and is presented as a derivative asset on the Condensed Consolidated Balance Sheet. At December 31, 2025, the fair value of the swap was a liability of $26 and was presented as a derivative liability on the Company’s Consolidated Balance Sheet. For the nine months ended September 30, 2026, the effective portion of changes in fair value of the interest-rate swap increased Other Comprehensive Income by $393, net of tax. For the year ended December 31, 2025, the effective portion of changes in fair value of the interest-rate swap decreased Other Comprehensive Income by $26. The swap is measured under fair value guidance using Level 2 inputs. No hedge ineffectiveness was recognized during the nine months ended September 30, 2026 or year ended December 31, 2025.

 

 

NOTE 12 – SUBSEQUENT EVENTS

 

On October 30, 2026, the Company entered into the First Amendment to the Credit Agreement with the Bank, which increased the maximum Senior Funded Debt to EBITDA ratio for the quarter ended September 30, 2026 and revised the financial covenants for subsequent periods (see Note 6).

 

16

  

 

ITEM 2. 

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and the related notes appearing elsewhere in this Quarterly Report on Form 10-Q (this “Quarterly Report”). This discussion and analysis may contain forward-looking statements based on assumptions about our future business. Unless otherwise stated, all dollar amounts are in thousands, except per share data.

 

Overview

 

FitLife Brands, Inc. (the “Company”) is a provider of innovative and proprietary nutritional supplements and wellness products for health-conscious consumers marketed under the following brand names: (i) NDS Nutrition, PMD Sports, SirenLabs, Core Active, Nutrology, and Metis Nutrition (together, the “NDS Products”); (ii) iSatori, BioGenetic Laboratories, and Energize (together, the “iSatori Products”); (iii) Dr. Tobias, All Natural Advice, and Maritime Naturals (together, the “MRC Products”); (iv) MusclePharm; and (v) Irwin Naturals, Applied Nutrition, and Nature’s Secret (together, the “Irwin Products”).

 

The Company distributes the NDS Products principally through franchised General Nutrition Centers, Inc. (“GNC”) stores located both domestically and internationally. The iSatori Products are sold through retail locations, which include specialty and mass market retailers, as well as online directly to the end consumer. The Company distributes the MRC Products primarily online through e-commerce platforms, such as Amazon.com (“Amazon”), directly to the end consumer. MusclePharm’s products are sold to both wholesale customers as well as online through various e-commerce platforms directly to the end consumer. Irwin Products are sold principally through wholesale channels in mass market and health food store segments, but also online directly to the end consumer.

 

FitLife Brands is headquartered in Omaha, Nebraska. For more information on the Company, please go to www.fitlifebrands.com. The Company’s common stock, par value $0.01 per share (“Common Stock”), trades under the symbol “FTLF” on the Nasdaq Capital Market.

 

First Amendment to the Credit Agreement

 

On October 30, 2026, the Company entered into a First Amendment to the Credit Agreement with the Bank (the “Amended Credit Agreement”). The Amended Credit Agreement restates the financial covenants for quarters ending September 30, 2026 through September 30, 2027 as follows:

 

 

●

Maximum Senior Funded Debt to EBITDA ratio: 3.25 to 1.00 for the quarters ending September 30 and December 31, 2026; 2.75 to 1.00 for March 31 and June 30, 2027; and 2.50 to 1.00 thereafter.

 

●

Minimum Fixed Charge Coverage Ratio: 1.00 to 1.00 for the quarters ending December 31, 2026 and March 31, 2027; 1.10 to 1.00 for June 30 and September 30, 2027; and 1.25 to 1.00 thereafter.

 

Acquisition of Irwin Naturals

 

On August 8, 2025, the Company acquired substantially all of the assets and assumed certain liabilities of Irwin Naturals and its related affiliates (“Irwin”) through an asset purchase transaction under Section 363 of the U.S. Bankruptcy Code. Total consideration for the acquisition was $42,500. Of this amount, $29,750 was funded using proceeds from a new term loan provided by the Bank, $6,000 was funded from a new $10,000 revolving line of credit from the Bank, and the remainder was funded from the Company’s available cash balances.

 

Restructuring

 

During the three months ended September 30, 2026, we implemented and substantially completed a restructuring initiative designed to improve operating efficiency, reduce our cost structure, and better align personnel and resources with the Company's current business needs and strategic priorities. In connection with the initiative, we recorded $280 of restructuring expense, primarily consisting of severance costs. As of September 30, 2026, $62 of these charges had been paid, with the remaining $218 accrued in accrued expenses. We expect the initiative to reduce annual operating expenses by approximately $1,200, with savings beginning to be realized in the fourth quarter of 2026. We do not expect to incur any significant additional costs to complete the initiative, which is currently expected to be fully completed by the end of the fourth quarter of 2026.

 

Stock Split

 

On February 7, 2025, the Company effected a 2-for-1 stock split of its Common Stock and proportionately increased the number of authorized shares of Common Stock. The shares of Common Stock retain a par value of $0.01 per share. Accordingly, an amount equal to the par value of the additional shares issued in the stock split was reclassified from additional paid-in capital in excess of par value to Common Stock.

 

17

 

Results of Operations

 

Comparison of the three months ended September 30, 2026 to the three months ended September 30, 2025

 

   

Three months ended

                 
   

September

30, 2026

   

September

30, 2025

   

Change ($)

   

Change

(%)

 
   

(Unaudited)

                 

Revenue

  $ 25,620     $ 23,485     $ 2,135       9 %

Cost of goods sold

    15,953       14,749       1,204       8 %

Gross profit

    9,667       8,736       931       11 %

Gross margin

    37.7 %     37.2 %             0.5 %

Advertising and marketing

    1,585       1,357       228       17 %

Selling, general and administrative (“SG&A”)

    5,177       4,105       1,072       26 %

Merger and acquisition related

    -       820       (820 )     (100 )%

Depreciation and amortization

    250       136       114       84 %

Total operating expense

    7,012       6,418       594       9 %

Operating income

    2,655       2,318       337       15 %

Other expense (income), net

    619       568       51       9 %

Provision for income tax

    465       829       (364 )     (44 )%

Net income

  $ 1,571     $ 921     $ 650       71 %

 

Revenue.  Revenue for the three months ended September 30, 2026 increased 9% to $25,620 compared to $23,485 for the three months ended September 30, 2025. The increase in revenue for the three months ended September 30, 2026 compared to the prior period is primarily due to the inclusion of a full quarter of Irwin’s operations (the Company acquired Irwin on August 8, 2025), partially offset by declining revenue from Legacy FitLife, as discussed below.

 

Legacy FitLife revenue for the three months ended September 30, 2026 was $12,604, a 24% decrease compared to the previous year, driven by an 18% decline in online revenue primarily attributable to MRC as well as a 34% decrease in wholesale revenue attributable to lower sales to certain retail partners, primarily GNC.

 

Wholesale revenue during the quarter ended September 30, 2026 was approximately 54% of net revenue, compared to 46% for online channels. Wholesale revenue during the quarter ended September 30, 2025 was 56% of net revenue compared to 44% for online channels during the same period.

 

Sales to customers in the U.S. were approximately 94% and 95% during the quarters ended September 30, 2026 and 2025, respectively, with the balance of sales to customers primarily in Canada.

 

Cost of Goods Sold.  Cost of goods sold for the three months ended September 30, 2026 increased to $15,953 as compared to $14,749 for the three months ended September 30, 2025. This 8% increase is primarily due to the increase in revenue from the acquisition of Irwin.

 

Gross Profit.  Gross profit for the three months ended September 30, 2026 increased to $9,667 as compared to $8,736 for the three months ended September 30, 2025. This 11% increase in gross profit is principally attributable to the acquisition of Irwin, partially offset by lower gross profit from Legacy FitLife.

 

Gross Margin. Gross margin for the three months ended September 30, 2026 increased to 37.7% from 37.2% for the comparable prior period. The increase in gross margin is primarily attributable to improved gross margin within Legacy FitLife. Gross margin during the three months ended September 30, 2025 was also adversely affected by $392 of amortization of inventory step-up. Excluding the amortization of the inventory step-up, gross margin for the three months ended September 30, 2025 would have been 38.9%.

 

Advertising and Marketing. Advertising and marketing expense for the three months ended September 30, 2026 increased to $1,585 as compared to $1,357 for the same period of the prior year. The 17% increase is primarily the result of advertising and marketing expense attributable to Irwin, partially offset by lower advertising and marketing expense attributable to Legacy FitLife.

 

SG&A. SG&A expense for the three months ended September 30, 2026 increased to $5,177 as compared to $4,105 for the three months ended September 30, 2025. The 26% increase in SG&A is primarily due to the inclusion of a full quarter of Irwin’s operations (the Company acquired Irwin on August 8, 2025). In addition, during the three months ended September 30, 2026, the Company recorded $280 of restructuring costs, which primarily consisted of severance and employee benefits.

 

18

 

Merger and Acquisition Related. For the three months ended September 30, 2026, there was no merger and acquisition related expense, compared to $820 during the same quarter of the prior year, which was driven by non-recurring transaction costs related to the Irwin acquisition during 2025.

 

Net Income.  We generated net income of $1,571 for the three months ended September 30, 2026, compared to net income of $921 for the three months ended September 30, 2025. The increase in net income was driven by the non-recurrence of merger and acquisition related expense associated with the acquisition of Irwin during the three months ended September 30, 2025, as well as a lower effective tax rate during the three months ended September 30, 2026. The increase also reflects the inclusion of a full quarter of Irwin's operations in the current-year period. These improvements were partially offset by lower gross profit from Legacy FitLife and $280 of restructuring costs incurred during the current-year period.

 

Comparison of the nine months ended September 30, 2026 to the nine months ended September 30, 2025

 

   

Nine months ended

                 
   

September

30, 2026

   

September

30, 2025

   

Change ($)

   

Change

(%)

 
   

(Unaudited)

                 

Revenue

  $ 77,494     $ 55,548     $ 21,946       40 %

Cost of goods sold

    48,499       33,034       15,465       47 %

Gross profit

    28,995       22,514       6,481       29 %

Gross margin

    37.4 %     40.5 %             (3.1 ) %

Advertising and marketing

    4,279       3,601       678       19 %

Selling, general and administrative (“SG&A”)

    14,895       9,102       5,793       64 %

Merger and acquisition related

    -       1,848       (1,848 )     (100 )%

Depreciation and amortization

    750       169       581       344 %

Total operating expense

    19,924       14,720       5,204       35 %

Operating income

    9,071       7,794       1,277       16 %

Other expense (income), net

    2,004       947       1,057       112 %

Provision for income tax

    1,826       2,161       (335 )     (16 )%

Net income

  $ 5,241     $ 4,686     $ 555       12 %

 

Revenue.  Revenue for the nine months ended September 30, 2026 increased 40% to $77,494 compared to $55,548 for the nine months ended September 30, 2025. The increase in revenue for the nine months ended September 30, 2026 compared to the prior period is primarily due to the acquisition of Irwin, partially offset by declining revenue from Legacy FitLife, as discussed below. The Irwin assets were acquired on August 8, 2025.

 

Legacy FitLife revenue for the nine months ended September 30, 2026 was $37,494, a 23% decrease compared to the previous year, driven by an 18% decline in online revenue, primarily attributable to MRC, as well as a 31% decrease in wholesale revenue attributable to lower sales to certain retail partners, primarily GNC.

 

Wholesale revenue during the nine months ended September 30, 2026 was approximately 55% of net revenue, compared to 45% for online channels for the same period in 2026.  Wholesale revenue during the nine months ended September 30, 2025 was 44% of net revenue compared to 56% for online channels during the same period. The decline in the percentage of revenue coming from online sales is primarily due to the acquisition of Irwin, which had minimal online revenue at the time of the acquisition.

 

Sales to customers in the U.S. were approximately 95% and 96% during the nine months ended September 30, 2026 and 2025, respectively, with the balance of sales to customers primarily in Canada.

 

Cost of Goods Sold.  Cost of goods sold for the nine months ended September 30, 2026 increased to $48,499 as compared to $33,034 for the nine months ended September 30, 2025. This 47% increase is primarily due to the increase in revenue from the acquisition of Irwin.

 

Gross Profit.  Gross profit for the nine months ended September 30, 2026 increased to $28,995 as compared to $22,514 for the nine months ended September 30, 2025. This 29% increase in gross profit is principally attributable to the acquisition of Irwin, partially offset by lower gross profit from Legacy FitLife.

 

Gross Margin. Gross margin for the nine months ended September 30, 2026 decreased to 37.4% from 40.5% for the comparable prior period. The decrease in gross margin is primarily attributable to the acquisition of Irwin, which historically generated a lower gross margin than FitLife. Gross margin during the nine months ended September 30, 2025 was also adversely affected by $392 of amortization of inventory step-up. Excluding the amortization of the inventory step-up, gross margin for the nine months ended September 30, 2025 would have been 41.2%.

 

19

 

Advertising and Marketing. Advertising and marketing expense for the nine months ended September 30, 2026 increased to $4,279 as compared to $3,601 for the same period of the prior year. The 19% increase is primarily the result of advertising and marketing expense attributable to Irwin, partially offset by lower advertising and marketing expense attributable to Legacy FitLife.

 

SG&A. SG&A expense for the nine months ended September 30, 2026 increased 64% to $14,895 as compared to $9,102 for the nine months ended September 30, 2025. The increase in SG&A is primarily due to the acquisition of Irwin. SG&A for the nine months ended September 30, 2026 also includes $280 of restructuring costs.

 

Merger and Acquisition Related. For the nine months ended September 30, 2026, there was no merger and acquisition related expense, compared to $1,848 during the same period of last year, which was driven by non-recurring transaction costs related to the Irwin acquisition during 2025.

 

Net Income.  We generated net income of $5,241 for the nine months ended September 30, 2026 as compared to net income of $4,686 for the nine months ended September 30, 2025. Net income for the nine months ended September 30, 2026 compared to the same period in 2025 increased by 12%, reflecting the acquisition of Irwin as well as the non-recurrence of merger and acquisition related expense associated with the acquisition of Irwin during the nine months ended September 30, 2025, partially offset by lower gross profit attributable to Legacy FitLife. 

 

Supplemental Discussion of Performance of Acquired Brands

 

One of the primary metrics used by management to evaluate the performance of the Company’s brands is contribution, a non-GAAP financial measure which management defines as gross profit less advertising and marketing expenditures. Other companies may also report contribution as a performance metric, but their definition or calculation of contribution may differ from the Company’s. Management believes that contribution, as defined by the Company, is a particularly relevant performance metric since it incorporates the gross profit associated with a specific brand or collection of brands as well as the advertising and marketing expense associated with the same brand or brands. With limited exceptions, other operating expense incurred by the Company is generally not allocable to a specific brand or collection of brands.  Management intends to provide this level of disclosure for approximately two years following a transaction, after which the performance of acquired brands will be reported as part of Legacy FitLife results. 

 

Other than for Irwin Products, the numbers in the contribution tables presented below represent the performance of a collection of brands. Legacy FitLife consists of thirteen brands. These collections of brands do not meet the definition of operating segments and are not managed as such.

 

Legacy FitLife

                                       

(Unaudited)

 

2025

   

2026

 
   

Q3

   

Q4

   

Q1

   

Q2

   

Q3

 

Wholesale revenue

  $ 6,686     $ 4,238     $ 3,798     $ 3,913     $ 4,417  

Online revenue

    9,978       9,028       8,678       8,501       8,187  

Total revenue

    16,664       13,266       12,476       12,414       12,604  

Gross profit

    6,542       5,395       5,143       5,177       5,247  

Gross margin

    39.3 %     40.7 %     41.2 %     41.7 %     41.6 %

Advertising and marketing

    1,285       1,077       887       941       1,017  

Contribution

  $ 5,257     $ 4,318     $ 4,256     $ 4,236     $ 4,230  

Contribution as a % of revenue

    31.5 %     32.5 %     34.1 %     34.1 %     33.6 %

 

For the third quarter of 2026, revenue for Legacy FitLife (which includes MusclePharm and MRC) declined 24% compared to the same period last year due to declines in both online and wholesale revenue.

 

Online revenue decreased by 18% compared to the third quarter of last year, primarily driven by lower online sales from MRC, partially offset by higher online sales for MusclePharm. Wholesale revenue decreased 34% compared to the third quarter of last year attributable to lower sales to certain retail partners, primarily GNC.

 

Gross margin for Legacy FitLife increased to 41.6% during the third quarter of 2026, compared to 39.3% during the third quarter of last year. Contribution as a percentage of revenue increased to 33.6% compared to 31.5% during the third quarter of last year. 

 

Irwin Naturals

                                       

(Unaudited)

 

2025

   

2026

 
   

Q3

   

Q4

   

Q1

   

Q2

   

Q3

 

Wholesale revenue

  $ 6,510     $ 11,216     $ 10,295     $ 10,695     $ 9,390  

Online revenue

    311       1,428       2,554       3,440       3,626  

Total revenue

    6,821       12,644       12,849       14,135       13,016  

Gross profit

    2,194       3,544       4,374       4,634       4,420  

Gross margin

    32.2 %     28.0 %     34.0 %     32.8 %     34.0 %

Advertising and marketing

    72       182       358       508       568  

Contribution

  $ 2,122     $ 3,362     $ 4,016     $ 4,126     $ 3,852  

Contribution as a % of revenue

    31.1 %     26.6 %     31.3 %     29.2 %     29.6 %

 

20

 

During the third quarter of 2026, Irwin generated 72% of its revenue from the wholesale channel and 28% from online sales. 

 

Online revenue during the third quarter of 2026 represents transactions through Irwin’s websites as well as through Amazon and other e-commerce platforms.  The Company began selling Irwin products on Amazon in mid-October of 2025, and sales have continued to increase since launch in October to an annual revenue run rate of over $12 million by the end of the third quarter of 2026.

 

For the third quarter of 2026, revenue for Irwin increased 91% compared to the same period last year due to increases in both wholesale and online sales. The 91% increase is primarily due to the inclusion of a full quarter of Irwin’s operations (the Company acquired Irwin on August 8, 2025).

 

Excluding the inventory step-up recorded in the third quarter of 2025, gross margin and contribution margin decreased to 34.0% and 29.6%, respectively, in the third quarter of 2026, compared to 37.9% and 36.9% in the prior-year period.

 

FitLife Consolidated

                                       

(Unaudited)

 

2025

   

2026

 
   

Q3

   

Q4

   

Q1

   

Q2

   

Q3

 

Wholesale revenue

  $ 13,196     $ 15,454     $ 14,093     $ 14,608     $ 13,807  

Online revenue

    10,289       10,456       11,232       11,941       11,813  

Total revenue

    23,485       25,910       25,325       26,549       25,620  

Gross profit

    8,736       8,939       9,517       9,811       9,667  

Gross margin

    37.2 %     34.5 %     37.6 %     37.0 %     37.7 %

Advertising and marketing

    1,357       1,259       1,245       1,449       1,585  

Contribution

  $ 7,379     $ 7,680     $ 8,272     $ 8,362     $ 8,082  

Contribution as a % of revenue

    31.4 %     29.6 %     32.7 %     31.5 %     31.5 %

 

For the third quarter of 2026 for the Company overall, revenue increased 9%, gross profit increased 11%, and contribution increased 10% as compared to the third quarter of 2025.

 

Excluding the inventory step-up recorded in the third quarter of 2025, gross margin and contribution margin decreased to 37.7% and 31.5%, respectively, in the third quarter of 2026, compared to 38.9% and 33.1% in the same period of the prior year.

 

Non-GAAP Measures

 

The financial presentation below contains certain financial measures not in accordance with GAAP, defined by the SEC as “non-GAAP financial measures”, including EBITDA and adjusted EBITDA. These measures may be different from non-GAAP financial measures used by other companies. The presentation of this financial information, which is not prepared under any comprehensive set of accounting rules or principles, is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in this Quarterly Report in accordance with GAAP.

 

21

 

As presented below, EBITDA excludes interest, foreign exchange gains and losses, income taxes, and depreciation and amortization. Adjusted EBITDA excludes—in addition to interest, foreign exchange gains and losses, taxes, depreciation and amortization—stock-based compensation, merger and acquisition related expense and other non-recurring items. The Company believes the non-GAAP measures provide useful information to both management and investors by excluding certain expense and other items that may not be indicative of its core operating results and business outlook. The Company believes that the inclusion of non-GAAP measures in the financial presentation below allows investors to compare the Company’s financial results with the Company’s historical financial results and is an important measure of the Company’s comparative financial performance.

 

   

For the three months

ended September 30,

   

For the nine months

ended September 30,

 
   

2026

   

2025

   

2026

   

2025

 
   

(Unaudited)

   

(Unaudited)

   

(Unaudited)

   

(Unaudited)

 

Net income

  $ 1,571     $ 921     $ 5,241     $ 4,686  

Interest expense, net

    654       562       2,068       955  

Foreign exchange gain

    (35 )     (43 )     (64 )     (57 )

Provision for income taxes

    465       829       1,826       2,161  

Depreciation and amortization

    250       136       750       169  

EBITDA

    2,905       2,405       9,821       7,914  

Non-cash and non-recurring adjustments

                               

Stock-based compensation

    96       126       171       332  

Merger and acquisition related

    -       820       -       1,848  

Amortization of inventory step-up

    -       392       -       392  

Writeoff of deferred financing costs

    -       49       -       49  

Restructuring costs

    280       -       280       -  

Adjusted EBITDA

  $ 3,281     $ 3,792     $ 10,272     $ 10,535  

 

Liquidity and Capital Resources

 

As of September 30, 2026, the Company had positive working capital of $13,064, compared to $11,459 at December 31, 2025. Our principal sources of liquidity at September 30, 2026 consisted of $689 of cash and $8,047 of accounts receivable. The increase in working capital is principally attributable to lower current liabilities, primarily accrued expense, and higher inventories and prepaid expense, partially offset by lower accounts receivable balances as of September 30, 2026 as compared to December 31, 2025.

 

On February 23, 2023, the Company and the Bank amended the Line of Credit Agreement (the “2023 Credit Agreement”) providing the Company with a term loan for the principal amount of $12,500 (“Term Loan A”). All of the proceeds from Term Loan A were used for the acquisition of MRC.

 

On October 10, 2023, the Company entered into a Second Amended and Restated Credit Agreement (the “Prior Credit Agreement”) with the Bank, amending and restating the 2023 Credit Agreement between the Company and the Bank. Pursuant to the Prior Credit Agreement, the Bank provided the Company with an additional term loan (“Term Loan B”, and together with Term Loan A, the “Term Loans”) for the principal amount of $10,000 and extended the maturity date of the Line of Credit of $3,500 to December 23, 2024. The Company used the proceeds from Term Loan B to fund the acquisition of the MusclePharm assets.

 

On December 19, 2024, the Company entered into the First Amendment to the Prior Credit Agreement (the “Amended Prior Credit Agreement”) to extend the maturity date of the $3,500 Line of Credit to April 30, 2026. Pursuant to the Amended Prior Credit Agreement, the Line of Credit accrued interest at an annual rate equal to the greater of 3.50% or the one-month secured overnight financing rate (“SOFR”) rate plus 2.75%, and each advance was payable on the maturity date with the interest on outstanding advances payable monthly. The Company was permitted, at its option, to prepay any borrowings under the Line of Credit, in whole or in part at any time prior to the maturity date, without premium or penalty.

 

On August 8, 2025 (the “Closing Date”), the Company entered into a new credit agreement (the “Credit Agreement”) with the Bank. Pursuant to the Credit Agreement, the Bank provided the Company with a five-year term loan in the amount of $40,625 (the “Irwin Term Loan”) and a three-year revolving line of credit of up to $10,000 (the “Credit Line”, and collectively with the Irwin Term Loan, the “Loan”). The Company used $29,750 from the Irwin Term Loan to complete the purchase of substantially all of the assets of Irwin, and its related affiliates, pursuant to an Asset Purchase and Sale Agreement, and $10,875 to pay off, retire and replace all existing debt of the Company as of the Closing Date.

 

22

 

Pursuant to the Credit Agreement, the Irwin Term Loan accrues interest at a per annum rate equal to 2.50% to 3.00%, based on leverage, above the secured overnight financing rate published by the Federal Reserve Bank of New York for the applicable selected interest period of one, three or six months (“Term SOFR Rate”, the Term SOFR Rate together with the aforementioned margin, the “Applicable Rate”). The Company shall make payments of accrued interest on the Irwin Term Loan at the end of each interest period and shall make principal payments on March 31, June 30, September 30, and December 31, of each calendar year. The Company began making quarterly payments of principal plus accrued interest on the Irwin Term Loan on December 31, 2025. Principal payments of $1,523 will be made quarterly through September 30, 2027, and each quarterly payment thereafter will be $2,031, in each case plus accrued interest. All remaining principal and accrued interest on the Irwin Term Loan will be due and payable in full on August 8, 2030.

 

Outstanding advances under the Credit Line (“Advances”) will accrue interest at the Applicable Rate, and the Company shall make payments of accrued interest on Advances at the end of each interest period and on the repayment of any Advance, with all remaining principal and accrued interest on the Advances being due and payable in full on August 8, 2028.

 

The Credit Agreement requires the Company (i) to maintain a maximum Senior Funded Debt to EBITDA ratio (as defined in the Credit Agreement), tested quarterly on a trailing twelve-month basis, and (ii) a minimum Fixed Charge Coverage Ratio (as defined in the Credit Agreement). On October 30, 2026, the Company entered into a First Amendment to the Credit Agreement with the Bank (the “Amended Credit Agreement”). The Amended Credit Agreement restates the financial covenants for quarters ending September 30, 2026 through September 30, 2027 as follows:

 

 

●

Maximum Senior Funded Debt to EBITDA ratio: 3.25 to 1.00 for the quarters ending September 30 and December 31, 2026; 2.75 to 1.00 for March 31 and June 30, 2027; and 2.50 to 1.00 thereafter.

 

●

Minimum Fixed Charge Coverage Ratio: 1.00 to 1.00 for the quarters ending December 31, 2026 and March 31, 2027; 1.10 to 1.00 for June 30 and September 30, 2027; and 1.25 to 1.00 thereafter.

 

After giving effect to the Amended Credit Agreement, the Company was in compliance with its financial covenants as of September 30, 2026.

 

As of September 30, 2026, the borrowings outstanding on the Irwin Term Loan and the Credit Line were $34,531 and $4,800, respectively, and $5,200 was available to borrow on the Credit Line.

 

The Company has historically financed its operations primarily through cash flow from operations and equity and debt financings. The Company currently anticipates that cash derived from operations and existing cash reserves, along with available borrowings under the Credit Line, will be sufficient to provide for the Company’s liquidity for the next twelve months. The Company’s material cash requirements over this period consist primarily of scheduled principal and interest payments under the Credit Agreement and working capital needs.

 

Cash Provided by Operating Activities. Cash provided by operating activities for the nine months ended September 30, 2026 was $4,445 compared to cash provided by operating activities of $7,195 for the nine months ended September 30, 2025. The decrease in cash provided by operating activities was primarily due to lower accounts payable and accrued expense balances compared to the same period of 2025, partially offset by lower accounts receivable.

 

Cash Used in Investing Activities. Cash used in investing activities for the nine months ended September 30, 2026 and 2025 was $0 and $42,537, respectively. The decrease in cash used in investing activities was due to the Irwin acquisition that occurred during the nine months ended September 30, 2025.

 

Cash Provided by (Used in) Financing Activities. Cash used in financing activities for the nine months ended September 30, 2026 was $5,371, primarily due to $4,571 of term loan repayments and $800 of net repayments on the Credit Line. Cash provided by financing activities of $34,009 for the nine months ended September 30, 2025 was primarily due to the borrowings under the Credit Agreement for the acquisition of Irwin on August 8, 2025, partially offset by loan repayments.

 

Critical Accounting Policies and Estimates

 

Our discussion and analysis of financial condition and results of operations is based upon our condensed consolidated financial statements, which have been prepared in accordance with GAAP. The preparation of these condensed consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, expense, and related disclosure of contingent assets and liabilities. We evaluate, on an on-going basis, our estimates and judgments, including those related to the useful life of the assets. We base our estimates on historical experience and assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.

 

The methods, estimates and judgments we use in applying our most critical accounting policies have a significant impact on the results that we report in our condensed consolidated financial statements. The SEC considers an entity’s most critical accounting policies to be those policies that are both most important to the portrayal of a company’s financial condition and results of operations and those that require management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about matters that are inherently uncertain at the time of estimation. For a more detailed discussion of the accounting policies of the Company, see Note 3 of the Notes to the Condensed Consolidated Financial Statements included in this Quarterly Report, “Summary of Significant Accounting Policies”. 

 

We believe the following critical accounting policies, among others, require significant judgments and estimates used in the preparation of our consolidated financial statements.

 

23

 

Use of Estimates and Assumptions

 

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect (i) the reported amounts of assets and liabilities, (ii) the disclosure of contingent assets and liabilities known to exist as of the date the financial statements are published, and (iii) the reported amount of net sales and expense recognized during the periods presented.

 

Those estimates and assumptions include estimates for reserves of uncollectible accounts receivable, allowance for inventory obsolescence, product returns, depreciable lives of property and equipment, allocation of purchase price from business combinations, analysis of impairment of goodwill, realization of deferred tax assets, accruals for potential liabilities and assumptions made in valuing stock instruments issued for services. Management evaluates these estimates and assumptions on a regular basis. Actual results could differ from those estimates.

 

Goodwill

 

The Company has determined that it has a single reporting unit for purposes of performing its goodwill impairment test. The Company reviews goodwill for impairment on an annual basis or whenever events or changes in circumstances indicate the carrying value may not be recoverable. The Company first assesses qualitative factors to determine whether it is more-likely-than-not that the fair value of the reporting unit is less than the carrying amount as a basis for determining whether it is necessary to perform an impairment test. If the qualitative assessment warrants further analysis, the Company compares the fair value of the reporting unit to its carrying value. The fair value of the reporting unit is determined using the market approach. The Company determines the amount of a potential goodwill impairment by comparing the fair value of the reporting unit with its carrying amount. To the extent the carrying value of a reporting unit exceeds its fair value, a goodwill impairment charge is recognized.

 

As the Company uses the market approach to determine fair value of the reporting unit, the price of its Common Stock is an important component of the fair value calculation. If the Company’s stock price experiences significant price fluctuations, this will impact the fair value of the reporting unit, which can lead to potential impairment in future periods.

 

Management determined there were no indicators of impairment at September 30, 2026 or December 31, 2025. The Company will perform its annual impairment analysis in December 2026.

 

Revenue Recognition

 

The Company’s revenue is comprised of sales of nutritional supplements and wellness products to consumers.

 

The Company accounts for revenue in accordance with FASB ASC 606. The underlying principle of ASC 606 is to recognize revenue to depict the transfer of goods or services to customers at the amount expected to be collected. ASC 606 creates a five-step model that requires entities to exercise judgment when considering the terms of contract(s), which includes (1) identifying the contract(s) or agreement(s) with a customer, (2) identifying our performance obligations in the contract or agreement, (3) determining the transaction price, (4) allocating the transaction price to the separate performance obligations, and (5) recognizing revenue as each performance obligation is satisfied. Under ASC 606, revenue is recognized when performance obligations under the terms of a contract are satisfied, which occurs for the Company upon shipment or delivery of products to our customers based on written sales terms. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring the products to a customer. 

 

All products sold by the Company are distinct individual products and consist of nutritional supplements and wellness products. The products are offered for sale solely as finished goods, and there are no performance obligations required post-shipment for customers to derive the expected value from them.

 

The Company’s products are also sold on e-commerce platforms including Amazon. For these transactions, the Company evaluated principal versus agent considerations to determine appropriateness of recording platform fees paid to Amazon as an expense or as a reduction of revenue. The Company records platform fees paid to Amazon for distribution of Company products to cost of goods sold in the condensed consolidated statements of income and comprehensive income. Distribution and platform fees are not recorded as a reduction of revenue because the Company (1) owns the goods before they are transferred to the customer, (2) can direct Amazon, similar to other third-party logistics providers (“Logistic Providers”), to return the Company’s inventory to any location specified by the Company, (3) has the responsibility to make customers whole following any returns made by customers directly to Logistic Providers and the Company retains the back-end inventory risk, (4) is subject to credit risk (i.e., credit card chargebacks), (5) establishes prices of its products, (6) can determine who fulfills the goods to the customer (Amazon or the Company) and (7) can limit quantities or stop selling the goods at any time. Based on these considerations, the Company is the principal in this arrangement.

 

The Company disaggregates revenue into distribution channels, geographical regions and collections of brands (Legacy FitLife and recently acquired brands). The Company determines that disaggregating revenue into these categories achieves the disclosure objective to depict how the nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factors.

 

Wholesale revenue during the quarter ended September 30, 2026 was approximately 54% of net revenue, compared to 46% for online channels for the same period. Wholesale revenue during the quarter ended September 30, 2025 was approximately 56% of net revenue, compared to 44% for online channels during the same period in 2025.

 

Wholesale revenue during the nine months ended September 30, 2026 was approximately 55% of net revenue, compared to 45% for online channels for the same period. Wholesale revenue during the nine months ended September 30, 2025 was approximately 44% of net revenue, compared to 56% for online channels during the same period in 2025.

 

24

 

Sales to customers in the U.S. were approximately 94% and 95%, respectively, during the three and nine months ended September 30, 2026, and approximately 95% and 96%, respectively, during the three and nine months ended September 30, 2025, with the balance of sales for the same respective periods being to customers primarily in Canada.

 

Control of products we sell transfers to customers upon shipment from our facilities or delivery to our customers, and the Company’s performance obligations are satisfied at that time. Shipping and handling activities are performed before the customer obtains control of the goods and therefore represent a fulfillment activity rather than promised goods to the customer. Payments for sales are generally made by check, credit card, or wire transfer. Historically the Company has not experienced any significant payment delays from customers.

 

For direct-to-consumer sales, with the exception of Irwin Products, the Company allows for returns within 30 days of purchase. Irwin allows for returns within 60 days of purchase for direct-to-consumer sales. Our wholesale customers, such as GNC, may return purchased products to the Company under certain circumstances, which include expired or soon-to-be-expired products located in GNC corporate stores or at any of its distribution centers, and products that are subject to a recall or that contain an ingredient or ingredients that are subject to a recall by the FDA.

 

A right of return does not represent a separate performance obligation, but because customers are allowed to return products, the consideration to which the Company expects to be entitled is variable. Such elements of variable consideration include, but are not limited to, estimated sales allowances, defective products, product returns and sales incentives, such as markdowns and sales promotions. The Company uses the most likely amount method to quantify the variable consideration. We assess our contracts and the reasonableness of our conclusions on a quarterly basis.

 

Recent Accounting Pronouncements

 

See Note 3 of the Condensed Consolidated Financial Statements included in this Quarterly Report for a description of recent accounting pronouncements believed by management to have a material impact on our present or future financial statements.

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Our business is conducted principally in the U.S.  However, due to the MRC acquisition in 2023, the Company now has more exposure to fluctuations in foreign currencies.  As a result, our financial results may be materially affected by factors such as changes in foreign currency exchange rates or economic conditions in foreign markets.

 

Foreign Currency

 

The Company has not entered into any foreign currency hedging transactions during the three and nine months ended September 30, 2026 or year ended December 31, 2025.

 

Interest Rates

 

Our exposure to risk for changes in interest rates relates primarily to borrowings under the Credit Agreement (which includes the Irwin Term Loan as well as our Credit Line), and our investments in short-term financial instruments. As of September 30, 2026 the Company had $34,531 outstanding on the Irwin Term Loan (of which $17,000 was swapped for a fixed rate, thereby eliminating interest rate variability on that portion of the loan) and $4,800 outstanding under its Credit Line.

 

Investments of our cash balances in both fixed-rate and floating-rate interest-earning instruments carry some interest rate risk. The fair value of fixed-rate securities may fall due to a rise in interest rates, while floating-rate securities may produce less income than expected if interest rates fall. Partly as a result of this, our future interest income will vary due to changes in interest rates and we may suffer losses in principal if we are forced to sell securities that have fallen in estimated fair value due to changes in interest rates. However, as substantially all of our cash equivalents consist of bank deposits and short-term money market instruments, we do not expect any material change with respect to our net income as a result of an interest rate change.

 

ITEM 4. CONTROLS AND PROCEDURES

 

 

a.

Evaluation of disclosure controls and procedures.

 

Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, an evaluation of the effectiveness of the design and operations of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as of September 30, 2026 was completed. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer believe that our disclosure controls and procedures are effective to ensure that information required to be disclosed in the reports submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, including to ensure that information required to be disclosed by the Company is accumulated and communicated to management, including the principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

 

25

 

 

b.

Changes in Internal Control Over Financial Reporting

 

There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the three months ended September 30, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

 

c.

Inherent Limitations on the Effectiveness of Controls

 

Management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control systems are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in a cost-effective control system, no evaluation of internal control over financial reporting can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been or will be detected.

 

These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of a simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures.

 

26

 

PART II

OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

We currently are not involved in any litigation that we believe could have a material adverse effect on our financial condition or results of operations. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of the Company or any of its subsidiaries, threatened against or affecting the Company, our Common Stock, any of our subsidiaries or of the Company’s or our subsidiaries’ directors or officers in their capacities as such, in which an adverse decision could have a material adverse effect.

 

ITEM 1A. RISK FACTORS

 

Our results of operations and financial condition are subject to numerous risks and uncertainties described in our comprehensive Annual Report on Form 10-K for our fiscal year ended December 31, 2025, filed with the SEC on March 31, 2026. Management is not aware of any material changes to the risk factors discussed in Part I, Item 1A, of the Annual Report on Form 10-K for the year ended December 31, 2025.  You should carefully consider these risk factors in conjunction with the other information contained in this Quarterly Report. Should any of these risks materialize, our business, financial condition and future prospects could be negatively impacted.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

None.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

 

There were no defaults upon senior securities during the three-month period ended September 30, 2026.

 

ITEM 5. OTHER INFORMATION

 

In the three months ended September 30, 2026, no directors or officers adopted or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.

 

ITEM 6. EXHIBITS

 

31.1

Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act.

31.2

Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act.

32.1

Certification of Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act.

32.2

Certification of Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act.

101.INS

Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

101.SCH

Inline XBRL Taxonomy Extension Schema Document

101.CAL

Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF

Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB

Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE

Inline XBRL Taxonomy Extension Presentation Linkbase Document

104

Cover Page Interactive Data File (embedded within the Inline XBRL Document and included in Exhibit 101)

 

27

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Registrant

FitLife Brands, Inc.

 
     

Date: November 16, 2026

By:

/s/ Dayton Judd

 
   

Dayton Judd

 
   

Chief Executive Officer and Chair

(Principal Executive Officer)

 

 

Registrant

FitLife Brands, Inc.

 
     

Date: November 16, 2026

By:

/s/ Jakob York

 
   

Jakob York

 
   

Chief Financial Officer

(Principal Financial Officer)

 

 

 

28

Keep reading